

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Advances in the understanding and clinical... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/5-2666/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/5-2666" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes" />
    
            <meta name="og:title" content="F1000Research Article: Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes.">
            <meta name="og:description" content="Read the latest article version by David Gonz&aacute;lez-de-Olano, Almudena Matito, Alberto Orfao, Luis Escribano, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="10302">
            <meta name="article-id" content="9565">
            <meta name="dc.title" content="Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes">
            <meta name="dc.description" content="Clonal mast cell activation syndromes and indolent systemic mastocytosis without skin involvement are two emerging entities that sometimes might be clinically difficult to distinguish, and they involve a great challenge for the physician from both a diagnostic and a therapeutic point of view. Furthermore, final diagnosis of both entities requires a bone marrow study; it is recommended that this be done in reference centers. In this article, we address the current consensus and guidelines for the suspicion, diagnosis, classification, treatment, and management of these two entities.">
            <meta name="dc.subject" content="Management, Mast Cell Activation Syndromes, Mastocytosis, Treatment">
            <meta name="dc.creator" content="Gonz&aacute;lez-de-Olano, David">
            <meta name="dc.creator" content="Matito, Almudena">
            <meta name="dc.creator" content="Orfao, Alberto">
            <meta name="dc.creator" content="Escribano, Luis">
            <meta name="dc.date" content="2016/11/14">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.9565.1">
            <meta name="dc.source" content="F1000Research 2016 5:2666">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Management ">
            <meta name="prism.keyword" content=" Mast Cell Activation Syndromes ">
            <meta name="prism.keyword" content=" Mastocytosis ">
            <meta name="prism.keyword" content=" Treatment">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2016/11/14">
            <meta name="prism.volume" content="5">
            <meta name="prism.number" content="2666">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.9565.1">
            <meta name="prism.url" content="https://f1000research.com/articles/5-2666">
            <meta name="citation_title" content="Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes">
            <meta name="citation_abstract" content="Clonal mast cell activation syndromes and indolent systemic mastocytosis without skin involvement are two emerging entities that sometimes might be clinically difficult to distinguish, and they involve a great challenge for the physician from both a diagnostic and a therapeutic point of view. Furthermore, final diagnosis of both entities requires a bone marrow study; it is recommended that this be done in reference centers. In this article, we address the current consensus and guidelines for the suspicion, diagnosis, classification, treatment, and management of these two entities.">
            <meta name="citation_description" content="Clonal mast cell activation syndromes and indolent systemic mastocytosis without skin involvement are two emerging entities that sometimes might be clinically difficult to distinguish, and they involve a great challenge for the physician from both a diagnostic and a therapeutic point of view. Furthermore, final diagnosis of both entities requires a bone marrow study; it is recommended that this be done in reference centers. In this article, we address the current consensus and guidelines for the suspicion, diagnosis, classification, treatment, and management of these two entities.">
            <meta name="citation_keywords" content="Management, Mast Cell Activation Syndromes, Mastocytosis, Treatment">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="David Gonz&aacute;lez-de-Olano">
            <meta name="citation_author_institution" content="Department of Allergy, Hospital Universitario Ram&oacute;n y Cajal, Madrid, 28034, Spain">
            <meta name="citation_author" content="Almudena Matito">
            <meta name="citation_author_institution" content="Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, 45071, Spain">
            <meta name="citation_author" content="Alberto Orfao">
            <meta name="citation_author_institution" content="Centro de Investigaci&oacute;n del C&aacute;ncer/IBMCC (CSIC/USAL), Departamento de Medicina, IBSAL and Servicio General de Citometr&iacute;a, University of Salamanca, Salamanca, 37007, Spain">
            <meta name="citation_author" content="Luis Escribano">
            <meta name="citation_author_institution" content="Centro de Investigaci&oacute;n del C&aacute;ncer/IBMCC (CSIC/USAL), Departamento de Medicina, IBSAL and Servicio General de Citometr&iacute;a, University of Salamanca, Salamanca, 37007, Spain">
            <meta name="citation_publication_date" content="2016/11/14">
            <meta name="citation_volume" content="5">
            <meta name="citation_publication_number" content="2666">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.9565.1">
            <meta name="citation_firstpage" content="2666">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/5-2666/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/5-2666.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=10302 /> <input type=hidden id=articleId name=articleId value=9565 /> <input type=hidden id=xmlUrl value="/articles/5-2666/v1/xml"/> <input type=hidden id=xmlFileName value="-5-2666-v1.xml"> <input type=hidden id=article_uuid value=2828ce9d-4c6e-44af-8c8a-377c6508a605 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.9565.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.9565.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/5-2666"
  },
  "headline": "Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation...",
  "datePublished": "2016-11-14T14:03:26",
  "dateModified": "2016-11-14T14:03:26",
  "author": [
    {
      "@type": "Person",
      "name": "David Gonz&aacute;lez-de-Olano"
    },    {
      "@type": "Person",
      "name": "Almudena Matito"
    },    {
      "@type": "Person",
      "name": "Alberto Orfao"
    },    {
      "@type": "Person",
      "name": "Luis Escribano"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Clonal mast cell activation syndromes and indolent systemic mastocytosis without skin involvement are two emerging entities that sometimes might be clinically difficult to distinguish, and they involve a great challenge for the physician from both a diagnostic and a therapeutic point of view. Furthermore, final diagnosis of both entities requires a bone marrow study; it is recommended that this be done in reference centers. In this article, we address the current consensus and guidelines for the suspicion, diagnosis, classification, treatment, and management of these two entities."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/5-2666",
            "name": "Advances in the understanding and clinical management of mastocytosis..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Advances in the understanding and clinical management of mastocytosis... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=10302 data-id=9565 data-downloads="" data-views="" data-scholar="10.12688/f1000research.9565.1" data-recommended="" data-doi="10.12688/f1000research.9565.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/5-2666/v1/pdf?article_uuid=2828ce9d-4c6e-44af-8c8a-377c6508a605" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-9565-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-9565-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-9565-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Gonz√°lez-de-Olano D, Matito A, Orfao A and Escribano L. Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2666 (<a class=new-orange href="https://doi.org/10.12688/f1000research.9565.1" target=_blank>https://doi.org/10.12688/f1000research.9565.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-9565-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=9565 id=track-article-signin-9565 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/9565?target=/articles/5-2666">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=10302 /> <input name=articleId type=hidden value=9565 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:dgolano@yahoo.es" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>David Gonz&aacute;lez-de-Olano</span></a><sup>1</sup><sup>*</sup>,&nbsp;</span><span class="">Almudena Matito<sup>2</sup><sup>*</sup>,&nbsp;</span><span class="">Alberto Orfao<sup>3</sup><sup>*</sup>,&nbsp;</span><span class="">Luis Escribano<sup>3</sup><sup>*</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:dgolano@yahoo.es" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>David Gonz&aacute;lez-de-Olano</span></a><sup>1</sup><sup>*</sup>,&nbsp;</span><span class="">Almudena Matito<sup>2</sup><sup>*</sup>,&nbsp;</span><span class="">Alberto Orfao<sup>3</sup><sup>*</sup>,&nbsp;</span><span class="">Luis Escribano<sup>3</sup><sup>*</sup></span></div> </div> <div class="authors extra-info"> <sup>*</sup> Equal contributors </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 14 Nov 2016 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.9565.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Allergy, Hospital Universitario Ram&oacute;n y Cajal, Madrid, 28034, Spain<br/> <sup>2</sup> Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, 45071, Spain<br/> <sup>3</sup> Centro de Investigaci&oacute;n del C&aacute;ncer/IBMCC (CSIC/USAL), Departamento de Medicina, IBSAL and Servicio General de Citometr&iacute;a, University of Salamanca, Salamanca, 37007, Spain<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=18049-17562></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=18048-17563></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Clonal mast cell activation syndromes and indolent systemic mastocytosis without skin involvement are two emerging entities that sometimes might be clinically difficult to distinguish, and they involve a great challenge for the physician from both a diagnostic and a therapeutic point of view. Furthermore, final diagnosis of both entities requires a bone marrow study; it is recommended that this be done in reference centers. In this article, we address the current consensus and guidelines for the suspicion, diagnosis, classification, treatment, and management of these two entities. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Management, Mast Cell Activation Syndromes, Mastocytosis, Treatment </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> David Gonz&aacute;lez-de-Olano (<a href="mailto:dgolano@yahoo.es">dgolano@yahoo.es</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> David Gonz√°lez-de-Olano </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> The authors declare that they have no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> This work was supported by grants from the Fondo de Investigaciones Sanitarias of the Ministerio de Sanidad y Consumo of Spain, Fundaci√≥n Mutua Madrile√±a, and Sociedad Espa√±ola Alergia e Inmunolog√≠a Cl√≠nica 2014 and 2015 (Spain). <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; ¬© 2016 Gonz√°lez-de-Olano D <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Gonz√°lez-de-Olano D, Matito A, Orfao A and Escribano L. Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2666 (<a href="https://doi.org/10.12688/f1000research.9565.1" target=_blank>https://doi.org/10.12688/f1000research.9565.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 14 Nov 2016, <b>5</b>(F1000 Faculty Rev):2666 (<a href="https://doi.org/10.12688/f1000research.9565.1" target=_blank>https://doi.org/10.12688/f1000research.9565.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 14 Nov 2016, <b>5</b>(F1000 Faculty Rev):2666 (<a href="https://doi.org/10.12688/f1000research.9565.1" target=_blank>https://doi.org/10.12688/f1000research.9565.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d6336e220>Introduction</h2><p class="" id=d6336e223>Mast cells (MCs) are a key structural and functional component of the immune system and play a key role in inflammatory reactions, and at the same time they are the main effector cells in allergic processes<sup><a href="#ref-1">1</a>‚Äì<a href="#ref-3">3</a></sup>. MC disorders might present with a great variety of clinical symptoms or signs, such as skin involvement, which might lead to suspicion of the disease. Nevertheless, among other MC disorders, two entities frequently represent a diagnostic and therapeutic challenge in routine clinical practice in allergy: (i) indolent systemic mastocytosis presenting without skin involvement (ISMs<sup>‚àí</sup>) and (ii) clonal mast cell activation syndrome (c-MCAS). Of note, both entities are closely related to anaphylaxis, and their diagnosis requires specific techniques. Here, we review the current consensus and guidelines for the diagnosis, classification, treatment, and management of these two entities.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d6336e239>Mastocytosis and other mast cell disorders: definition and classification</h2><div class=section><a name=d6336e242 class=n-a></a><h3 class=section-title>Mastocytosis</h3><p class="" id=d6336e247>The term systemic mastocytosis (SM) is used to define a heterogeneous group of rare diseases characterized by the presence of abnormal MCs in various organs and tissues<sup><a href="#ref-4">4</a></sup>. Two critical biological findings which are linked to the pathogenesis of the disease have been described: (i) activating somatic mutations in the <i>KIT</i> gene (usually the <i>KIT</i> Asp816Val D816V mutation) and the presence of an aberrant immunophenotype associated with the expression of CD25 on (bone marrow [BM]) clonal MCs. The current World Health Organization (WHO) classification of the disease includes up to seven distinct categories that meet the diagnostic criteria for mastocytosis (<a href="#T1">Table 1</a>). However, the development of new, more sensitive and specific methods, such as multi-parameter flow cytometry and highly sensitive polymerase chain reaction (PCR)-based techniques for the detection of aberrant MCs present at very low frequencies<sup><a href="#ref-5">5</a>‚Äì<a href="#ref-8">8</a></sup> and the study of the <i>KIT</i> mutation in purified cells<sup><a href="#ref-9">9</a></sup> or blood<sup><a href="#ref-10">10</a>‚Äì<a href="#ref-12">12</a></sup> or both, have led to an unprecedentedly increased rate of detection of phenotypically aberrant and <i>KIT</i> mutated MCs in BM and peripheral blood, pointing out not only the potential need to revise current diagnostic and classification criteria to recognize new entities with very low tumor burden associated with life-threatening symptoms such as anaphylaxis but also a potential impact on the long-term prognosis of patients with indolent forms of the disease.</p><div class="table-wrap panel clearfix"><a name=T1 class=n-a></a><div class=caption><h3>Table 1. World Health Organization 2016 criteria for the diagnosis and classification of systemic mastocytosis<sup><a href="#ref-4">4</a></sup>.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d6336e303 class=n-a></a><thead><a name=d6336e305 class=n-a></a><tr><a name=d6336e307 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d6336e309 class=n-a></a>Classification of mastocytosis</th><th align=left colspan=1 rowspan=1><a name=d6336e312 class=n-a></a>Diagnosis</th></tr></thead><tbody><a name=d6336e317 class=n-a></a><tr><a name=d6336e319 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e321 class=n-a></a>Cutaneous mastocytosis<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- Maculopapular cutaneous mastocytosis<sup><a href="#note-1">a</a></sup><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- Diffuse cutaneous mastocytosis<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- Mastocytoma of skin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e333 class=n-a></a>- &gt;15 mast cells (MCs) aggregating or more than 20 MCs per high-<br class=br>power field microscopy √ó(40) in skin biopsy<br class=br>- Absence of systemic mastocytosis (SM) criteria</td></tr><tr><a name=d6336e341 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e343 class=n-a></a>SM<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- Indolent SM&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(with or without skin involvement)<br class=br><br class=br><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- Smoldering SM<br class=br><br class=br><br class=br><br class=br><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- Aggressive SM<br class=br><br class=br><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- SM with an associated hematological<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;neoplasm<br class=br><br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- MC leukemia</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e371 class=n-a></a><br class=br>- SM criteria<br class=br>- Absence of C-findings<sup><a href="#note-2">b</a></sup> and other clonal hematological diseases<br class=br>-&lt;20% of MCs in bone marrow (BM) sections<br class=br><br class=br>- SM criteria<br class=br>- Absence of C-findings<sup><a href="#note-2">b</a></sup> and other clonal hematological diseases<br class=br>but two or more B-findings<sup><a href="#note-2">b</a></sup><br class=br><br class=br>- SM criteria<br class=br>- C-findings<sup><a href="#note-2">b</a></sup><br class=br><br class=br>- SM criteria<br class=br>- Demonstration of a clonal hematological non-MC disease<br class=br><br class=br>- SM criteria<br class=br>- &gt;20% of MCs in BM sections</td></tr><tr><a name=d6336e418 class=n-a></a><td colspan=1 rowspan=1><a name=d6336e420 class=n-a></a>MC sarcoma</td><td colspan=1 rowspan=1><a name=d6336e423 class=n-a></a><br class=br>&nbsp;- Infiltration of an extracutaneous organ by undifferentiated MCs<br class=br>&nbsp;&nbsp;with a destructive growth pattern</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d6336e434 class=n-a></a><p id=note-1> <sup>a</sup>Formerly known as urticaria pigmentosa. Main type of cutaneous mastocytosis<sup><a href="#ref-82">82</a></sup>.</p><p id=note-2><sup>b</sup>B-findings include (i) infiltration grade (MC) in BM of more than 30% and serum tryptase of more than 200 ng/mL, (ii) dysmyelopoiesis, and (iii) organomegaly without impariment of organ function<sup><a href="#ref-4">4</a></sup>. C-findings indicate organ dysfunction due to widespread MC infiltration, including cytopenias, osteolysis, malabsorption, and organomegaly with functional impairment of the organ/tissue (hypersplenism, portal hypertension, ascites)<sup><a href="#ref-4">4</a></sup>.</p><p id=d6336e458>Diagnostic criteria: At least one major criterion and one minor criterion or at least three minor criteria must be fulfilled for the diagnosis of SM to established. Major diagnostic criteria: multifocal dense infiltrates of MCs (&gt;15 MCs aggregating) detected in BM sections and/or other extracutaneous organ(s) by tryptase immunohistochemistry or other MC-associated stains. Minor diagnostic criteria: (1) more than 25% of MCs are spindle-shaped in MC infiltrates detected in BM sections or other extracutaneous tissue sections OR of more than 25% atypical MCs (type I plus type II) detected in BM smears; (2) detection of a <i>KIT</i> point mutation at codon 816 in BM MCs or other extracutaneous organ(s); (3) expression of CD25 or CD2 (or both) on MCs in BM MCs, blood, or other extracutaneous tissues; (4) total serum baseline tryptase concentration persistently more than 20 ng/mL (in case of an associated hematologic non-MC lineage disease, this criterion is not valid).</p></div></div></div></div><div class=section><a name=d6336e468 class=n-a></a><h3 class=section-title>Indolent systemic mastocytosis</h3><p class="" id=d6336e473>Based on previous reports in the largest series of patients, indolent systemic mastocytosis (ISM) comprises around 80% of all SM cases<sup><a href="#ref-13">13</a></sup>. Among them, around 20% of patients lack skin lesions at presentation (ISMs<sup>‚àí</sup>)<sup><a href="#ref-14">14</a></sup>. Despite the great relevance and efficiency of the WHO criteria for the diagnosis of SM, in ISMs<sup>‚àí</sup>, MCs represent only a very small proportion of all nucleated BM cells (usually fewer than 10<sup>‚àí3</sup> BM MCs, as assessed by flow cytometry)<sup><a href="#ref-15">15</a></sup>, and BM MC aggregates are frequently (around 30% of cases) not found in such patients with SM<sup><a href="#ref-15">15</a></sup>, in the absence of significantly increased serum baseline tryptase levels (&lt;20 Œºg/L). Consequently, the use of highly sensitive and specific methodological approaches to the study of BM MCs becomes critical in order to avoid a misdiagnosis in patients presenting with low tumor burden<sup><a href="#ref-16">16</a></sup>.</p></div><div class=section><a name=d6336e507 class=n-a></a><h3 class=section-title>Mast cell activation syndromes</h3><p class="" id=d6336e512>The term MC activation syndrome (MCAS) encompasses a heterogeneous group of diseases which are characterized by systemic symptoms secondary to MC mediator release that (i) might or might not have a known trigger, (ii) might or might not be associated with immunoglobulin E (IgE)-specific antibodies in response to that trigger, (iii) are associated with normal or elevated baseline tryptase levels, and (iv) do not show skin lesions of mastocytosis<sup><a href="#ref-17">17</a></sup>. In <a href="#T2">Table 2</a>, the most frequent and relevant clinical symptoms suggesting an underlying MCAS are listed, and <a href="#T3">Table 3</a> depicts the diagnostic criteria for MCAS.</p><div class="table-wrap panel clearfix"><a name=T2 class=n-a></a><div class=caption><h3>Table 2. Main symptoms and signs associated with the release of mast cell mediators which are considered to substantially contribute to the clinical manifestation of mast cell activation syndrome.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d6336e536 class=n-a></a><thead><a name=d6336e538 class=n-a></a><tr><a name=d6336e540 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d6336e542 class=n-a></a>Mediator</th><th align=left colspan=1 rowspan=1><a name=d6336e545 class=n-a></a>Symptoms and signs</th></tr></thead><tbody><a name=d6336e550 class=n-a></a><tr><a name=d6336e552 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d6336e554 class=n-a></a>Histamine</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e557 class=n-a></a>Headache, hypotension, urticaria with or without<br class=br>angioedema, pruritus, diarrhea</td></tr><tr><a name=d6336e563 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d6336e565 class=n-a></a>Tryptase</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e568 class=n-a></a>Endothelial activation with associated inflammatory<br class=br>reaction</td></tr><tr><a name=d6336e574 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d6336e576 class=n-a></a>Chymase</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e579 class=n-a></a>Hypertension, arrythmia</td></tr><tr><a name=d6336e583 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d6336e585 class=n-a></a>Proteoglycan (heparin)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e588 class=n-a></a>Bleeding diathesis</td></tr><tr><a name=d6336e592 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d6336e594 class=n-a></a>Platelet-activating factor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e597 class=n-a></a>Abdominal cramping, pulmonary edema, urticaria,<br class=br>bronchoconstriction, hypotension, arrythmia</td></tr><tr><a name=d6336e604 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d6336e606 class=n-a></a>Prostaglandin D2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e609 class=n-a></a>Mucus secretion, bronchoconstriction, vascular<br class=br>instability</td></tr><tr><a name=d6336e615 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d6336e617 class=n-a></a>LTC4 and LTD4</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e620 class=n-a></a>Mucus secretion, edema formation, vascular instability</td></tr><tr><a name=d6336e624 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d6336e626 class=n-a></a>Proinflammatory cytokines</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e629 class=n-a></a>Local inflammation, edema formation, leukocyte<br class=br>migration</td></tr><tr><a name=d6336e635 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d6336e637 class=n-a></a>Chemokines</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e640 class=n-a></a>Acute inflammation and leukocyte recruitment,<br class=br>leukocyte migration</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d6336e650 class=n-a></a><p id=d6336e652> LT, leukotriene. Adapted with permission from Karger<sup><a href="#ref-17">17</a></sup>.</p></div></div></div><div class="table-wrap panel clearfix"><a name=T3 class=n-a></a><div class=caption><h3>Table 3. Criteria for the diagnosis of mast cell activation syndrome<sup><a href="#ref-17">17</a></sup>.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d6336e677 class=n-a></a><thead><a name=d6336e679 class=n-a></a><tr><a name=d6336e681 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d6336e683 class=n-a></a>Criteria</th></tr></thead><tbody><a name=d6336e688 class=n-a></a><tr><a name=d6336e690 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e692 class=n-a></a>1. Typical clinical symptoms<sup><a href="#note-3">a</a></sup></td></tr><tr><a name=d6336e699 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e701 class=n-a></a>2. Increase in serum total tryptase by at least 20% above baseline plus 2 ng/mL<br class=br>during or within 4 hours after a symptomatic period</td></tr><tr><a name=d6336e707 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e709 class=n-a></a>3. Response of clinical symptoms to histamine receptor<sup><a href="#note-4">b</a></sup> blockers or ‚Äúmast cell-<br class=br>targeting‚Äù agents (for example, cromolyn)</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d6336e723 class=n-a></a><p id=note-3> <sup>a</sup>Different clinical symptoms are suggestive of systemic mast cell activation syndrome (MCAS). The following reached a consensus level above 70%<sup><a href="#ref-17">17</a></sup>: flushing, pruritus, urticaria, angioedema, nasal congestion, nasal pruritus, wheezing, throat swelling, headache, hypotension, and diarrhea. None of them <i>per se</i> is specific for MCAS and thus can count as MCAS criteria only in the context of the other two criteria.</p><p id=note-4><sup>b</sup>Histamine receptor blockers: H1 ¬± H2 inverse agonists</p><p id=d6336e742>Reproduced with permission from Karger<sup><a href="#ref-17">17</a></sup></p></div></div></div><p class="" id=d6336e751>The current classification of MCAS is shown in <a href="#T4">Table 4</a>. Based on the experience of the Spanish Network of Mastocytosis (REMA), the most relevant objective criteria to subclassify MCAS rely on the presence versus absence of clonal MCs as defined by the expression of CD25 (for example, CD25<sup>+</sup> versus CD25<sup>‚àí</sup>) or a <i>KIT</i> mutation, particularly <i>KIT</i> D816V, or both. When MCAS diagnostic criteria are fulfilled but there is no evidence of clonality, non-clonal-MCAS should be considered and co-existence of allergy or other underlying diseases should be confirmed or ruled out<sup><a href="#ref-18">18</a></sup>.</p><div class="table-wrap panel clearfix"><a name=T4 class=n-a></a><div class=caption><h3>Table 4. Classification of mast cell activation syndrome<sup><a href="#ref-17">17</a></sup>.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d6336e790 class=n-a></a><thead><a name=d6336e792 class=n-a></a><tr><a name=d6336e794 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d6336e796 class=n-a></a>Diagnostic categories and variants</th><th align=left colspan=1 rowspan=1><a name=d6336e799 class=n-a></a>Proposed criteria</th></tr></thead><tbody><a name=d6336e804 class=n-a></a><tr><a name=d6336e806 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e808 class=n-a></a>Primary mast cell activation syndrome<br class=br>(MCAS)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e813 class=n-a></a>MCAS and clonality criteria are met (CD25<sup>+</sup><br class=br>or <i>KIT</i> D816V mutated MCs or both)<sup><a href="#note-5">a</a></sup></td></tr><tr><a name=d6336e827 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e829 class=n-a></a>&nbsp;&nbsp;&nbsp;Mastocytosis</td><td align=left colspan=1 rowspan=1><a name=d6336e832 class=n-a></a></td></tr><tr><a name=d6336e835 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e837 class=n-a></a>&nbsp;&nbsp;&nbsp;Clonal or monoclonal MCAS (c-MCAS)</td><td align=left colspan=1 rowspan=1><a name=d6336e840 class=n-a></a></td></tr><tr><a name=d6336e843 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e845 class=n-a></a>Secondary MCAS</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e848 class=n-a></a>MCAS, allergy, or other mast cell (MC)-<br class=br>activating diseases criteria are met</td></tr><tr><a name=d6336e854 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e856 class=n-a></a>&nbsp;&nbsp;&nbsp;Allergy</td><td align=left colspan=1 rowspan=1><a name=d6336e859 class=n-a></a></td></tr><tr><a name=d6336e863 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e865 class=n-a></a>&nbsp;&nbsp;&nbsp;Other underlying diseases<sup><a href="#note-6">b</a></sup></td><td align=left colspan=1 rowspan=1><a name=d6336e871 class=n-a></a></td></tr><tr><a name=d6336e874 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e876 class=n-a></a>Idiopathic<sup><a href="#note-7">c</a></sup> MCAS</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e883 class=n-a></a>MCAS criteria are met but the diagnosis of<br class=br>the disease that explains MC activation is<br class=br>not achieved</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d6336e895 class=n-a></a><p id=note-5> <sup>a</sup>CD25<sup>+</sup> <i>KIT</i> D816V mutated MC or <i>KIT</i> D816V mutated MCs without CD25<sup>+</sup> expression</p><p id=note-6> <sup>b</sup>Includes autoimmune diseases, bacterial infections, and drug adverse reactions</p><p id=note-7> <sup>c</sup>This is an exclusion diagnosis and therefore a complete study is needed in order to discard any known disease that might cause MC activation</p><p id=d6336e927>Reproduced with permission from Karger<sup><a href="#ref-17">17</a></sup></p></div></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d6336e940>Clinical features of patients with primary mast cell activation syndromes: mastocytosis and clonal mast cell activation syndrome</h2><p class="" id=d6336e943>Symptoms due to the release of MC mediators upon MC activation might be present in every category of MCAS, including mild, severe, or even life-threatening symptoms such as pruritus, flushing, gastrointestinal complaints (abdominal pain or diarrhea), cognitive symptoms, and even anaphylaxis<sup><a href="#ref-19">19</a>,<a href="#ref-20">20</a></sup>.</p><p class="" id=d6336e953>In indolent systemic mastocytosis with skin lesions (ISMs<sup>+</sup>), MC activation symptoms are typically heterogeneous and might vary from recurrent anaphylaxis<sup><a href="#ref-21">21</a>,<a href="#ref-22">22</a></sup> to occasional symptoms triggered by a varying number of different stimuli linked to the MC mediator release episodes (<a href="#T5">Table 5</a>). In turn, ISMs<sup>‚àí</sup> are frequently characterized by serious episodes of MC mediator release triggered by different factors‚Äîfor example, mainly insect sting, drugs, and foods‚Äîor they might be idiopathic<sup><a href="#ref-23">23</a></sup>; in both situations, such episodes are significantly associated with the presence of anaphylaxis with cardiovascular or vascular collapse symptoms, in the absence of both urticaria and angioedema<sup><a href="#ref-23">23</a></sup>. Early studies by the REMA have demonstrated that ISMs<sup>‚àí</sup> patients present unique features that distinguish them from ISMs<sup>+</sup> cases<sup><a href="#ref-23">23</a></sup>: (i) a higher prevalence of men versus women, (ii) a lower frequency of symptoms outside of acute episodes, (iii) lower BM MC burden, and (iv) the presence of the <i>KIT</i> mutation usually restricted to the MC lineage<sup><a href="#ref-23">23</a>,<a href="#ref-24">24</a></sup>. Of note, such unique disease features are even more characteristic within ISMs<sup>‚àí</sup> patients whose symptoms are triggered exclusively by insect stings, whereas ISMs<sup>‚àí</sup> patients with other triggering factors show clinical characteristics at presentation which are more similar to those of ISMs<sup>+</sup> cases<sup><a href="#ref-24">24</a></sup>.</p><div class="table-wrap panel clearfix"><a name=T5 class=n-a></a><div class=caption><h3>Table 5. Triggers of mast cell mediator release in mast cell activation syndrome and recommendations of avoidance.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d6336e1026 class=n-a></a><thead><a name=d6336e1028 class=n-a></a><tr><a name=d6336e1030 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d6336e1032 class=n-a></a>Trigger</th><th align=left colspan=1 rowspan=1><a name=d6336e1035 class=n-a></a>Recommendations</th></tr></thead><tbody><a name=d6336e1040 class=n-a></a><tr><a name=d6336e1042 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1044 class=n-a></a>Physical agents</td><td align=left colspan=1 rowspan=1><a name=d6336e1047 class=n-a></a></td></tr><tr><a name=d6336e1050 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d6336e1052 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- Heat, changes in temperature</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1055 class=n-a></a>- Use air conditioning when necessary and mildly warm water for bath/<br class=br>shower</td></tr><tr><a name=d6336e1061 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1063 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- Friction on mastocytomas</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1066 class=n-a></a>- Avoid Darier‚Äôs sign</td></tr><tr><a name=d6336e1070 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1072 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- Manipulation of the GI system<br class=br>(for example, during surgery)</td><td align=left colspan=1 rowspan=1><a name=d6336e1077 class=n-a></a>- Consider prophylactic anti-mediator therapy</td></tr><tr><a name=d6336e1081 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1083 class=n-a></a>Emotional factors</td><td align=left colspan=1 rowspan=1><a name=d6336e1086 class=n-a></a></td></tr><tr><a name=d6336e1090 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1092 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- Stress, anxiety</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1095 class=n-a></a>- Consider anxiolytics or relaxation techniques or both</td></tr><tr><a name=d6336e1099 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d6336e1101 class=n-a></a>Drugs</td><td align=left colspan=1 rowspan=1><a name=d6336e1104 class=n-a></a></td></tr><tr><a name=d6336e1107 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d6336e1109 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- NSAIDs<sup><a href="#note-8">a</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1115 class=n-a></a>- Use drugs with known tolerance for each case and consider drug<br class=br>challenge testing whenever tolerance is unknown and the drug required</td></tr><tr><a name=d6336e1121 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d6336e1123 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- Opioids</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1126 class=n-a></a>- Use drugs with known tolerance for each case and consider drug<br class=br>challenge testing whenever tolerance is unknown and the drug required</td></tr><tr><a name=d6336e1132 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d6336e1134 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- Anesthetics<sup><a href="#note-9">b</a>,<a href="#note-10">c</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1143 class=n-a></a>- Use drugs with known tolerance for each case and consider prophylactic<br class=br>anti-mediator therapy and anesthetic drugs with the safest profile</td></tr><tr><a name=d6336e1149 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d6336e1151 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- Radiological contrast media<sup><a href="#note-10">c</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1157 class=n-a></a>- Use contrast media with known tolerance for each case and consider<br class=br>prophylactic anti-mediator therapy and use low-molecular-weight contrast<br class=br>agents</td></tr><tr><a name=d6336e1166 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1168 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- Interferon Œ±2b</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1171 class=n-a></a>- Consider prophylactic anti-mediator therapy before first doses</td></tr><tr><a name=d6336e1175 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1177 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- Cladribine<sup><a href="#note-11">d</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1183 class=n-a></a>- Consider prophylactic anti-mediator therapy before first doses</td></tr><tr><a name=d6336e1187 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1189 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- Vaccines<sup><a href="#note-10">c</a>,<a href="#note-8">e</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1198 class=n-a></a>- Consider prophylactic anti-mediator therapy</td></tr><tr><a name=d6336e1202 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1204 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- Dextrans</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1207 class=n-a></a>- Use low-molecular-weight dextran or alternative solutions</td></tr><tr><a name=d6336e1211 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1213 class=n-a></a>Insect sting and bites</td><td align=left colspan=1 rowspan=1><a name=d6336e1216 class=n-a></a></td></tr><tr><a name=d6336e1219 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d6336e1221 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- Hymenoptera</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1224 class=n-a></a>- Use insect repellents; avoid perfumed lotions; wear light-colored clothes,<br class=br>long-sleeved shirts, and long pants; avoid going barefoot; patients with<br class=br>history of previous insect-induced anaphylaxis must carry an emergency<br class=br>kit; specific immunotherapy for IgE-mediated hymenoptera venom allergy is<br class=br>recommended</td></tr><tr><a name=d6336e1237 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1239 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>- Hippobosca equina</i>, mosquito<sup><a href="#note-13">f</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1248 class=n-a></a>- Use insect repellents; avoid perfumed lotions; wear light-colored clothes,<br class=br>long-sleeved shirts, and long pants; avoid going barefoot; patients with<br class=br>history of previous insect-induced anaphylaxis must carry an emergency kit</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d6336e1260 class=n-a></a><p id=note-8> <sup>a</sup>Frequency of mast cell (MC) mediator-related symptoms of 2% in pediatric mastocytosis and 14% in adult mastocytosis<sup><a href="#ref-83">83</a></sup></p><p id=note-9> <sup>b</sup>Frequency of MC mediator-related symptoms and anaphylaxis of 2% and 0.4% in adult mastocytosis, respectively<sup><a href="#ref-84">84</a></sup>; 4% of MC mediator-related symptoms and 0‚Äì2% of anaphylaxis in pediatric mastocytosis<sup><a href="#ref-84">84</a>‚Äì<a href="#ref-86">86</a></sup></p><p id=note-10> <sup>c</sup>Prophylactic anti-mediator therapy is recommended in all cases<sup><a href="#ref-87">87</a></sup></p><p id=note-11><sup>d</sup>Infrequent, based on one case report (Javed Sheik, Beth Israel Hospital, Harvard Medical School, personal communication, September 2002)</p><p id=note-12><sup>e</sup>Infrequent, based on case report<sup><a href="#ref-88">88</a></sup></p><p id=note-13><sup>f</sup>Infrequent, based on case reports<sup><a href="#ref-89">89</a>,<a href="#ref-90">90</a></sup></p><p id=d6336e1321>GI, gastrointestinal; IgE, immunoglobulin E; NSAID, non-steroidal anti-inflammatory drug. Adapted with permission from Ergon<sup><a href="#ref-91">91</a></sup>.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d6336e1334>Diagnosis of primary mast cell activation syndromes</h2><p class="" id=d6336e1337>The final diagnosis of SM and c-MCAS systematically requires a BM study for the evaluation of all disease characteristics used for the diagnosis of SM, such as BM MC cytology<sup><a href="#ref-29">25</a></sup>, histology and immunochemistry<sup><a href="#ref-26">26</a>,<a href="#ref-27">27</a></sup>, flow cytometry immunophenotyping using specific gating strategies for the detection of BM MCs present at low frequencies<sup><a href="#ref-5">5</a>‚Äì<a href="#ref-7">7</a>,<a href="#ref-28">28</a></sup>, and the study of <i>KIT</i> mutation in purified MCs<sup><a href="#ref-9">9</a>,<a href="#ref-29">29</a></sup>, together with a detailed clinical work-up. Usually, these studies are available only in reference centers, and therefore either the patient or the samples should be referred.</p><p class="" id=d6336e1371>The European Competence Network on Mastocytosis recommends using the REMA score (<a href="#f1">Figure 1</a>) as a clinically useful tool to predict for the presence of clonal MCs prior to a BM study<sup><a href="#ref-23">23</a></sup>; the REMA score is based only on demographic data (gender), the symptoms and signs observed during the acute episodes, and serum baseline tryptase levels. A REMA score of at least 2 predicts with a high sensitivity and specificity for ISMs<sup>‚àí</sup> (or c-MCAS), whereas a REMA score of less than 2 usually indicates non-clonal disease. Whether ‚Äúnon-clonal disease‚Äù means a true absence of any mutations whatsoever or simply the absence of clonality currently detectable in the clinical laboratory remains unclear. The REMA score is a particularly helpful tool since (i) it is based on clinical data and can be used on a routine clinical basis, (ii) it is associated with rather low costs, and (iii) it avoids unnecessary BM studies.</p><div class="fig panel clearfix"><a name=f1 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/10302/b7dabba4-d467-489c-a96e-ffd9fa26736b_figure1.gif"><img alt="b7dabba4-d467-489c-a96e-ffd9fa26736b_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/10302/b7dabba4-d467-489c-a96e-ffd9fa26736b_figure1.gif"></a><div class=caption><h3>Figure 1. The Spanish Network on Mastocytosis score.</h3><p id=d6336e1394>This scoring model is proposed as a screening tool for the diagnosis of clonal mast cells in patients presenting with anaphylaxis in the absence of skin mastocytosis before a bone marrow study is performed. MCAS, mast cell activation syndrome. Reproduced with permission from Elsevier Inc.<sup><a href="#ref-23">23</a></sup>.</p></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d6336e1408>Approach to diagnosis of primary mast cell activation syndromes</h2><p class="" id=d6336e1411>Whenever a patient is suspected of having a primary MCAS (either mastocytosis without skin involvement or c-MCAS), the use of the REMA score mentioned above is recommended<sup><a href="#ref-23">23</a></sup> as an initial screening measure (<a href="#f2">Figure 2</a>). Patients with a REMA score of less than 2 will have a low probability of presenting clonal MCs; therefore, in such cases, it is usually not necessary to conduct additional studies other than controlling the symptoms with adequate medication and scheduling periodic follow-up visits. In contrast, patients with a REMA score of at least 2 have a high probability of presenting mastocytosis or c-MCAS. Thus, in the latter patients, it is recommended that appropriate treatment be started and that the patient be evaluated in detail for major complications of the disease, such as hepatomegaly/splenomegaly, osteopenia, and osteoporosis. To establish the most appropriate timing to perform a BM biopsy to arrive at a firm diagnosis, it might be useful to evaluate the presence of the D816V <i>KIT</i> mutation in peripheral blood (it is typically positive in approximately 80% of primary MCAS cases<sup><a href="#ref-12">12</a></sup>) and to monitor baseline serum tryptase levels and wait until they rise above 20 ng/mL, at which point the probability of obtaining a BM sample that is suitable for demonstrating BM involvement increases. Independently of the time at which the BM study is scheduled, it is recommended that BM MCs be purified prior to molecular studies, which have demonstrated greater sensitivity for the detection of <i>KIT</i> mutations<sup><a href="#ref-9">9</a>,<a href="#ref-23">23</a>,<a href="#ref-30">30</a></sup>. As an exception, BM biopsy studies might be performed in suspicious patients with a REMA score of at least 2 and baseline tryptase levels of less than 20 ng/mL who presented with anaphylaxis following a hymenoptera sting and who are candidates for immunotherapy, since patients with mastocytosis or c-MCAS (or both) have a greater risk of having adverse reactions during administration of venom immunotherapy (VIT)<sup><a href="#ref-14">14</a></sup> (see the ‚ÄòHymenoptera venom immunotherapy‚Äô section below). A new quantitative real-time PCR test for KIT-D816V that is substantially more sensitive than standard KIT-D816V PCR testing has recently been developed, as the quantitative reverse transcription-PCR (qrt-PCR) test is showing essentially 100% sensitivity<sup><a href="#ref-31">31</a></sup>. Unfortunately, the availability of the qrt-PCR test at present is far more limited than that of the standard PCR test.</p><div class="fig panel clearfix"><a name=f2 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/10302/b7dabba4-d467-489c-a96e-ffd9fa26736b_figure2.gif"><img alt="b7dabba4-d467-489c-a96e-ffd9fa26736b_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/10302/b7dabba4-d467-489c-a96e-ffd9fa26736b_figure2.gif"></a><div class=caption><h3>Figure 2. Updated algorithm proposed by REMA for the management of MCAS patients suspected of having mastocytosis without skin lesions and c-MCAS.</h3><p id=d6336e1460>Clonality in this figure (as in <a href="#f1">Figure 1</a>) is limited to positivity for KIT-D816V by polymerase chain reaction or positivity for co-expression by flow cytometry of CD117 with CD25 or CD2 or both.</p><p id=d6336e1466><sup>1</sup>In asymptomatic patients, only sodium cromoglicate. Depending on additional symptoms, assess adding other anti-mediator treatments.</p><p id=d6336e1471><sup>2</sup>Periodic determination of tryptase together with follow-up of clinical evolution and, if necessary, image tests.</p><p id=d6336e1476><sup>3</sup>Tryptase values are approximate and are based on the fact that, in patients with low values, the percentage of MCs in bone marrow is very low and therefore the possibility of finding aggregates or identifying MCs is more complicated.</p><p id=d6336e1482><sup>4</sup>In cases where there is a rising trend in baseline tryptase values, clinicians are advised to wait until it rises above 20 ng/mL, at which point the probability of obtaining a sample that is suitable for conducting the study increases. The unique situation in which a bone marrow biopsy can be assessed in patients with a score of at least 2 and baseline tryptase levels of less than 20 ng/mL occurs when the patient has presented anaphylaxis following a hymenoptera sting and is a candidate for immunotherapy, given that patients with mastocytosis or c-MCAS (or both) have a greater risk of having adverse reactions during the administration of venom immunotherapy.</p><p id=d6336e1487><sup>5</sup>The bone marrow study should be done only if the mentioned methods (see text, section ‚ÄúDiagnosis of primary mast cell activation syndromes‚Äù), and flow cytometry and cell purification in particular, are available. If the technology needed to conduct these studies is not available, it is recommended that patients be referred to specialized reference centers.</p><p id=d6336e1492>c-MCAS, clonal mast cell activation syndrome; ISM<sup>‚àí</sup>, indolent systemic mastocytosis without skin lesions; MC, mast cell; MCAS, mast cell activation syndrome; PB, peripheral blood; REMA, Spanish Network on Mastocytosis. Adapted with permission from Ergon<sup><a href="#ref-91">91</a></sup>.</p></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d6336e1510>Treatment of primary mast cell activation syndromes</h2><p class="" id=d6336e1513>Patients with c-MCAS or mastocytosis may present symptoms due to the release of MC mediators, associated or not with symptoms related to tissue infiltration by clonal MC (more frequent among aggressive forms of mastocytosis). At present, there is no curative therapy for mastocytosis and the treatment strategies are focused on controlling the frequency and intensity of symptoms secondary to the release of MC mediators; this includes both strict avoidance of triggers (<a href="#T5">Table 5</a>) and the anti-mediator therapy carefully selected on the basis of the intensity or severity (or both) of the signs and symptoms linked with the activation of MCs. Cytoreductive therapy and targeted therapies with tyrosine kinase inhibitors might be needed in selected cases presenting with elevated MC burden or aggressive and poor prognosis-associated forms of SM or patients who are unresponsive to conventional anti-mediator therapy<sup><a href="#ref-32">32</a></sup>, but these therapies will not be discussed further in this review.</p><div class=section><a name=d6336e1523 class=n-a></a><h3 class=section-title>Avoidance of triggers and counseling</h3><p class="" id=d6336e1528>Careful counseling must be given to patients, caretakers, and their physicians to avoid triggers that evoke MC mediator release<sup><a href="#ref-32">32</a>,<a href="#ref-33">33</a></sup> (<a href="#T5">Table 5</a>). In addition, detailed training to manage MC activation-associated episodes should be provided to patients as well as their physicians.</p></div><div class=section><a name=d6336e1542 class=n-a></a><h3 class=section-title>Anti-mediator therapy for primary mast cell activation disorders</h3><p class="" id=d6336e1547>Anti-mediator therapy for primary MCAS aims at inhibiting production, interfering with release, blocking the specific receptors, or antagonizing the effects of MC mediators. It is used both to treat and to prevent acute and chronic MC mediator release-associated symptoms<sup><a href="#ref-32">32</a></sup>. The specific anti-mediator administration schedule (on demand or continuous administration) should be carefully selected for the individual patient on the basis of the intensity or severity (or both) of the signs and symptoms observed during the most severe acute episodes or anaphylaxis as well as the MC mediator-related symptoms recorded between acute episodes<sup><a href="#ref-19">19</a></sup>.</p><p class="" id=d6336e1558><b><i>Histamine receptor blockers.</i></b> The biologic effects of histamine released from MCs, through its binding to histamine receptors (mainly H1 and H2 histamine receptors), include (i) increased vascular permeability, (ii) vasodilatation, (iii) contraction of non-vascular smooth muscle, (iv) increase of exocrine gland secretion, and (v) stimulation of the peripheral nervous system; these effects result in symptoms such as pruritus, urticaria, edema, bronchoconstriction, gastric hypersecretion, abdominal cramping, diarrhea, headache, hypotension, and anaphylaxis<sup><a href="#ref-34">34</a></sup>. The effects of H1 blockers are described in <a href="#T6">Table 6</a>.</p><div class="table-wrap panel clearfix"><a name=T6 class=n-a></a><div class=caption><h3>Table 6. Antimediator therapy used to control for MC mediators related symptoms: drugs most frequently used, their mechanisms of action and controlled symptoms.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d6336e1582 class=n-a></a><thead><a name=d6336e1584 class=n-a></a><tr><a name=d6336e1586 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d6336e1588 class=n-a></a>Drug</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6336e1591 class=n-a></a>Mechanism of action</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6336e1594 class=n-a></a>Controlled symptoms</th></tr></thead><tbody><a name=d6336e1599 class=n-a></a><tr><a name=d6336e1601 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1603 class=n-a></a>H1 antihistamines</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1606 class=n-a></a>Histamine receptor blocker</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1609 class=n-a></a>Pruritus, flushing, urticaria, swelling, tachycardia,<br class=br>abdominal pain related with MC degranulation processes,<br class=br>hypotension or reduction of the severity of symptoms of<br class=br>anaphylaxis<sup><a href="#ref-32">32</a>,<a href="#ref-34">34</a>,<a href="#ref-42">42</a>,<a href="#ref-92">92</a>,<a href="#ref-93">93</a></sup></td></tr><tr><a name=d6336e1634 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1636 class=n-a></a>H2 antihistamines</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1639 class=n-a></a>- Histamine receptor blocker that can potentiate the<br class=br>effect of H1 antihistamines</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1644 class=n-a></a>Gastric hypersecretion, abdominal pain, diarrhea, and<br class=br>recurrent/severe MC mediator release episodes<sup><a href="#ref-32">32</a>,<a href="#ref-40">40</a>,<a href="#ref-42">42</a>,<a href="#ref-94">94</a>,<a href="#ref-95">95</a></sup></td></tr><tr><a name=d6336e1665 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1667 class=n-a></a>Sodium cromol</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1670 class=n-a></a>- Unclear<br class=br>- Inhibits GTP-g-S-induced exocytosis in MCs and<br class=br>modulates sensory nerve function<sup><a href="#ref-106">106</a>,<a href="#ref-107">107</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1683 class=n-a></a>Abdominal pain, vomiting, diarrhea (based on double-<br class=br>blind placebo-controlled trials), pruritus, flushing,<br class=br>headache, cognitive and skeletal symptoms<sup><a href="#ref-40">40</a>,<a href="#ref-45">45</a>,<a href="#ref-96">96</a>‚Äì<a href="#ref-105">105</a></sup></td></tr><tr><a name=d6336e1703 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1705 class=n-a></a>Aspirin and NSAIDs</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1708 class=n-a></a>Inhibition of cyclooxygenase and blockade of the<br class=br>synthesis of PGD2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1713 class=n-a></a>Flushing, dizziness, and gastrointestinal symptoms<sup><a href="#ref-48">48</a>,<a href="#ref-108">108</a></sup></td></tr><tr><a name=d6336e1723 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1725 class=n-a></a>Montelukast</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1728 class=n-a></a>Antagonizes cysLT receptor 1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1731 class=n-a></a>Respiratory, cutaneous, gastrointestinal, and urinary<br class=br>symptoms<sup><a href="#ref-47">47</a>,<a href="#ref-109">109</a>‚Äì<a href="#ref-111">111</a></sup></td></tr><tr><a name=d6336e1747 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1749 class=n-a></a>Zileuton</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1752 class=n-a></a>Blockade of the synthesis of LTs by inhibiting LO</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1755 class=n-a></a>Neuropsychiatric and constitutional subjective<br class=br>symptoms</td></tr><tr><a name=d6336e1761 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1763 class=n-a></a>Glucocorticoids</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1766 class=n-a></a>- Binding the intracellular glucocorticoid receptor and<br class=br>modulation of the transcription mediator of numerous<br class=br>genes<br class=br>- Decreased number of connective tissue MCs<br class=br>- Inhibition of the production of stem cell factor<br class=br>production and other interleukins and eicosanoid<br class=br>mediators<br class=br>- Decreased expression of chemokine receptors (for<br class=br>example, CCR3)<br class=br>- Decreased MC activation via induction of decreased<br class=br>expression of FcŒµRI<br class=br>- Inhibition of signaling cascades in MCs through the<br class=br>expression of phosphatases that are upregulated by<br class=br>glucocorticoids<sup><a href="#ref-42">42</a>,<a href="#ref-114">114</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1803 class=n-a></a>Gastrointestinal malabsorption, abdominal pain, ascites,<br class=br>bone disease (including diffuse bone sclerosis); acute<br class=br>and/or severe MC release<sup><a href="#ref-40">40</a>,<a href="#ref-112">112</a>,<a href="#ref-113">113</a></sup></td></tr><tr><a name=d6336e1820 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1822 class=n-a></a>Omalizumab</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1825 class=n-a></a>Blocks the binding of IgE to the FcŒµRI receptor on<br class=br>the surface of MCs and basophils, reducing receptor<br class=br>expression<sup><a href="#ref-123">123</a></sup> and the release of mediators<sup><a href="#ref-124">124</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d6336e1839 class=n-a></a>Cutaneous symptoms<sup><a href="#ref-115">115</a>‚Äì<a href="#ref-117">117</a></sup>, gastrointestinal symptoms<sup><a href="#ref-118">118</a>,<a href="#ref-119">119</a></sup>,<br class=br>anaphylaxis<sup><a href="#ref-118">118</a>,<a href="#ref-120">120</a>‚Äì<a href="#ref-122">122</a></sup>, and reactions to venom<br class=br>immunotherapy<sup><a href="#ref-58">58</a></sup></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d6336e1879 class=n-a></a><p id=d6336e1881> GTP-g-S, guanosine triphosphate-gamma-S; IgE, immunoglobulin E; LO, lipoxygenase; LT, leukotriene; MC, mast cell; NSAID, non-steroidal anti-inflammatory drug; PGD2, prostaglandin D2.</p></div></div></div><p class="" id=d6336e1887>Some H1 antihistamines such as desloratadine and ketotifen have MC-stabilizing properties, and therefore they might also decrease the release of MC mediators<sup><a href="#ref-35">35</a>,<a href="#ref-36">36</a></sup>. Ketotifen has been reported to be effective in the treatment of bone disease as well as cutaneous, gastrointestinal, and neuropsychiatric symptoms in mastocytosis<sup><a href="#ref-37">37</a>‚Äì<a href="#ref-39">39</a></sup>. Patients with associated depression might benefit from doxepin because of its effects as an antidepressant and H1 histamine blocker<sup><a href="#ref-40">40</a></sup>. Rupatadine also has an antagonistic effect against platelet-activating factor, a lipid-derived mediator which is newly synthesized and released by MCs upon their activation, resulting in hypotensive episodes and flushing<sup><a href="#ref-41">41</a></sup>.</p><p class="" id=d6336e1913>Some patients with mastocytosis require a combination of different H1 blockers to achieve a good control of symptoms<sup><a href="#ref-32">32</a></sup>. The use of non-sedating H1 blockers is recommended for patients who require daily maintenance therapy; in turn, the use of sedating H1 antihistamines that have a fast-acting effect which makes them suitable drugs to treat acute MC mediator release episodes, frequently in association with corticosteroids or epinephrine or both, and also to prevent MC degranulation during risk situations might be administered at night or on demand<sup><a href="#ref-32">32</a>,<a href="#ref-42">42</a></sup>.</p><p class="" id=d6336e1927><b><i>Cromolyn sodium.</i></b> Cromolyn sodium is an MC stabilizer that has been proven to inhibit MC activation and MC release of mediators both <i>in vitro</i> and <i>in vivo</i> despite its limited systemic absorption following ingestion; this suggests an inability of the drug to enter cells and the need for a potential interaction with an as-yet-unidentified cell surface receptor to induce its biologic activity<sup><a href="#ref-43">43</a></sup> (<a href="#T6">Table 6</a>). Side effects include headache, sleepiness, irritability, abdominal pain, diarrhea, and constipation, most of which are attenuated by progressive introduction of the drug<sup><a href="#ref-44">44</a></sup>. In addition, 0.21‚Äì4% cromolyn sodium water-soluble creams, as well as aqueous-based skin lotion, may be effective at improving cutaneous symptoms (for example, pruritus and flaring of lesions)<sup><a href="#ref-32">32</a>,<a href="#ref-34">34</a>,<a href="#ref-45">45</a>,<a href="#ref-46">46</a></sup>.</p><p class="" id=d6336e1964><b><i>Antagonists of arachidonic acid metabolites.</i></b> MCs synthesize <i>de novo</i> mediators and release arachidonic acid metabolites through the action of lipoxygenase and cyclooxygenase enzymes; thus, they produce leukotrienes and prostaglandins (PGs), respectively. Prostaglandin D2 is generated almost entirely by MCs and rapidly converted into active metabolites of prolonged activity rather than the parent compound, such as Œ±11Œ≤-PGF2; the two PGs share a biological activity and induce bronchoconstriction, increase of vascular permeability, and vasodilatation, and at the same time they have chemoattractive properties for eosinophils, basophils, and Th2 lymphocytes<sup><a href="#ref-47">47</a></sup> and are involved in the development of flushing and possibly also hypotensive episodes in patients with c-MCAS and mastocytosis<sup><a href="#ref-48">48</a></sup> (<a href="#T6">Table 6</a>).</p><p class="" id=d6336e1984><b><i>Aspirin.</i></b> Non-steroidal anti-inflammatory drugs, especially aspirin, can also inhibit the activation of MCs and their degranulation in some patients with mastocytosis; therefore, this therapy is recommended in patients with known tolerance to these drugs.</p><p class="" id=d6336e1990><b><i>Glucocorticoids.</i></b> The mechanism of action and the effects of glucocorticoids are shown in <a href="#T6">Table 6</a>. Short cycles of low doses of either prednisone (0.3 mg/kg per day) or oral budesonide (0.1 mg/kg per day) may improve abdominal pain refractory to treatment with cromolyn. Topical corticosteroids may be used for patients who present with skin symptoms, especially among cases with limited skin involvement; however, evidence supporting their topical use is either anecdotal or based on small series of patients<sup><a href="#ref-49">49</a></sup>.</p><p class="" id=d6336e2003><b><i>Anti-immunoglobulin E therapy.</i></b> Successful anti-IgE therapy has been documented in some conditions such as severe persistent allergic asthma, chronic urticaria<sup><a href="#ref-50">50</a></sup>, idiopathic anaphylaxis<sup><a href="#ref-51">51</a></sup>, and mastocytosis (<a href="#T6">Table 6</a>). Until more information based on clinical trials becomes available, omalizumab in MC diseases should be restricted to selected patients with severe symptoms which have proven unresponsive to intensive anti-mediator therapy<sup><a href="#ref-33">33</a></sup>.</p><p class="" id=d6336e2025><b><i>Hymenoptera venom immunotherapy.</i></b> Specific VIT is recommended for mastocytosis and c-MCAS patients with IgE-mediated anaphylaxis to hymenoptera venom; however, it should be managed as a high-risk procedure. VIT has proven effective and safe in these patients<sup><a href="#ref-52">52</a>‚Äì<a href="#ref-56">56</a></sup>; it has a rate of protection from re-stings of 86%, and the frequency of systemic reactions to VIT ranges from 5‚Äì25%<sup><a href="#ref-14">14</a>,<a href="#ref-57">57</a></sup>, most of which (75%) were associated with rush inductions (versus 25% using conventional induction)<sup><a href="#ref-57">57</a></sup>. Whenever adverse reactions to VIT prevent the protective maintenance dose of 100 Œºg per month from being reached, prophylactic anti-mediator therapy, changes in the extract, and administration of omalizumab therapy may be useful<sup><a href="#ref-57">57</a>,<a href="#ref-58">58</a></sup>. Furthermore, in patients who present anaphylaxis after re-sting, despite the administration of a standard maintenance dose, it is recommended that maintenance doses be increased to 200 Œºg<sup><a href="#ref-57">57</a></sup>. An extended maintenance administration (even lifelong) is proposed<sup><a href="#ref-14">14</a>,<a href="#ref-57">57</a></sup> since cases presenting with fatal reactions after discontinuation of VIT have been described<sup><a href="#ref-59">59</a>,<a href="#ref-60">60</a></sup>.</p></div><div class=section><a name=d6336e2076 class=n-a></a><h3 class=section-title>Other therapies</h3><p class="" id=d6336e2081><b><i>Ultraviolet irradiation.</i></b> <i>In vitro</i> studies demonstrated that long-wave ultraviolet radiation (psoralen plus ultraviolet A or ultraviolet A alone) and narrowband ultraviolet B phototherapy irradiation interfere with the release of histamine from skin-activated MCs and induce MC apoptosis<sup><a href="#ref-61">61</a>‚Äì<a href="#ref-63">63</a></sup>; all of them were employed as a second-line therapy to treat cutaneous symptoms (pruritus, whealing, and flare reactions) in patients with typical mastocytosis skin lesions who were not responsive to first-line therapies with anti-mediator drugs<sup><a href="#ref-40">40</a>,<a href="#ref-64">64</a>‚Äì<a href="#ref-66">66</a></sup>. There is no information regarding whether these therapies are useful in ISMs<sup>‚àí</sup> and c-MCAS cases. In addition, fading of hyperpigmented skin lesions (frequently temporary) can be observed in some cases. Furthermore, responses of life-threatening MC mediator release episodes in children with bullous diffuse cutaneous mastocytosis have been reported<sup><a href="#ref-67">67</a></sup>.</p><p class="" id=d6336e2114><b><i>Treatment of bone mass loss.</i></b> This is a frequent finding in both ISMs<sup>+</sup> and advanced mastocytosis but is less frequently observed among primary MCAS cases, particularly ISMs<sup>‚àí</sup> and c-MCAS. Fractures are usually developed as a consequence of severe osteoporosis or large osteolytic lesions. Local MC infiltration and disturbances in bone remodeling which are due to the release of MC mediators such as interleukin-6 (IL-6), histamine, heparin, receptor activator of nuclear factor kappa-B ligand, osteoprotegerin, or sclerostin are involved in the pathogenesis of bone manifestations in mastocytosis<sup><a href="#ref-68">68</a>,<a href="#ref-69">69</a></sup>. Calcium and vitamin D supplements, combined with bisphosphonates, are usually the first choice for osteopenia and osteoporosis, respectively<sup><a href="#ref-70">70</a>‚Äì<a href="#ref-72">72</a></sup>. Other therapies such as estrogen replacement in postmenopausal women and denosumab or interferon-alpha<sup><a href="#ref-73">73</a>,<a href="#ref-74">74</a></sup> in patients with severe osteoporosis at risk of pathologic bone fractures unresponsive to conventional treatments might also be considered. Regarding peptidergic/peptidomimetic drugs such as teriparatide, caution is urged since these drugs have been associated with driving MC activation via MRGPRX2<sup><a href="#ref-75">75</a></sup>.</p><p class="" id=d6336e2152><b><i>Selective serotonin reuptake inhibitors.</i></b> MCs contain numerous mediators, including neurotransmitters (for example, serotonin), cytokines, and chemokines, that play a role in stress response, behavior, and emotion regulation<sup><a href="#ref-76">76, 77</a></sup>. Furthermore, the elevation of the circulating levels of tumor necrosis factor-alpha and IL-6 with, for example, endotoxin leads to depressive symptoms, and it has been previously described that some selective serotonin reuptake inhibitors (SSRIs) such as citalopram can reduce endotoxin-induced symptoms<sup><a href="#ref-78">78</a></sup>. Based on this information, together with their good tolerability profile, SSRIs have emerged as an option to improve symptoms of depression in patients with mastocytosis<sup><a href="#ref-79">79</a></sup>.</p></div><div class=section><a name=d6336e2172 class=n-a></a><h3 class=section-title>Other conditions</h3><p class="" id=d6336e2177>With regard to pregnancy, two different series of women with mastocytosis have been reported in the literature<sup><a href="#ref-80">80</a>,<a href="#ref-81">81</a></sup>. The larger series<sup><a href="#ref-81">81</a></sup> included 45 pregnancies and deliveries in women with non-aggressive categories of the disease. Based on their results, anti-mediator therapy (dexchlorpheniramine, loratadine, cetirizine, ranitidine, oral corticosteroids, and adrenaline), if required during pregnancy, as well as systematic administration of prophylactic anti-mediator therapy at the beginning of labor based on drugs with a good well-known safety profile, is recommended<sup><a href="#ref-81">81</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d6336e2199>Abbreviations</h2><p class="" id=d6336e2202>BM, bone marrow; c-MCAS, clonal mast cell activation syndrome; IgE, immunoglobulin E; IL, interleukin; ISM, indolent systemic mastocytosis; MC, mast cell; MCAS, mast cell activation syndrome; PCR, polymerase chain reaction; PG, prostaglandin; qrt-PCR, quantitative reverse transcription-polymerase chain reaction; REMA, Spanish Network on Mastocytosis; SM, systemic mastocytosis; SSRI, selective serotonin reuptake inhibitor; VIT, venom immunotherapy; WHO, World Health Organization.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d6336e1 class=n-a></a><h2 class=main-title id=d6726>Competing interests</h2><p class=metadata-entry><a name=d6336e152 class=n-a></a><p id=d6336e153> The authors declare that they have no competing interests.</p></p></div><div class=back-section><a name=d6336e1 class=n-a></a><h2 class=main-title id=d6728>Grant information</h2><p>This work was supported by grants from the Fondo de Investigaciones Sanitarias of the Ministerio de Sanidad y Consumo of Spain, Fundaci√≥n Mutua Madrile√±a, and Sociedad Espa√±ola Alergia e Inmunolog√≠a Cl√≠nica 2014 and 2015 (Spain).</p><p> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i></p></div><div class=back-section><a name=d6336e2209 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d7105>References</h2><div class="section ref-list"><a name=d6336e2209 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d6336e2216 class=n-a></a>Fukuoka Y, Xia H, Sanchez-Mu√±oz LB, <i> et al.</i>: Generation of anaphylatoxins by human beta-tryptase from C3, C4, and C5. <i>J Immunol.</i> 2008; <b>180</b>(9): 6307‚Äì16. <a target=xrefwindow id=d6336e2227 href="http://www.ncbi.nlm.nih.gov/pubmed/18424754">PubMed Abstract </a> | <a target=xrefwindow id=d6336e2230 href="http://dx.doi.org/10.4049/jimmunol.180.9.6307">Publisher Full Text </a> | <a target=xrefwindow id=d6336e2234 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2645414">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d6336e2243 class=n-a></a>Galli SJ, Dvorak AM, Dvorak HF: Basophils and mast cells: morphologic insights into their biology, secretory patterns, and function. <i>Prog Allergy.</i> 1984; <b>34</b>: 1‚Äì141. <a target=xrefwindow id=d6336e2251 href="http://www.ncbi.nlm.nih.gov/pubmed/6230674">PubMed Abstract </a> | <a target=xrefwindow id=d6336e2254 href="http://dx.doi.org/10.1159/000318367">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d6336e2263 class=n-a></a>Metzger H: The high affinity receptor for IgE on mast cells. <i>Clin Exp Allergy.</i> 1991; <b>21</b>(3): 269‚Äì79. <a target=xrefwindow id=d6336e2271 href="http://dx.doi.org/10.1111/j.1365-2222.1991.tb01658.x">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d6336e2280 class=n-a></a>Arber DA, Orazi A, Hasserjian R, <i> et al.</i>: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. <i>Blood.</i> 2016; <b>127</b>(20): 2391‚Äì405. <a target=xrefwindow id=d6336e2291 href="http://www.ncbi.nlm.nih.gov/pubmed/27069254">PubMed Abstract </a> | <a target=xrefwindow id=d6336e2294 href="http://dx.doi.org/10.1182/blood-2016-03-643544">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d6336e2303 class=n-a></a>Orfao A, Escribano L, Villarrubia J, <i> et al.</i>: Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples: identification and enumeration. <i>Am J Pathol.</i> 1996; <b>149</b>(5): 1493‚Äì9. <a target=xrefwindow id=d6336e2314 href="http://www.ncbi.nlm.nih.gov/pubmed/8909239">PubMed Abstract </a> | <a target=xrefwindow id=d6336e2317 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1865253">Free Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d6336e2327 class=n-a></a>Escribano L, Naval√≥n R, Nu√±ez R, <i> et al.</i>: Immunophenotypic analysis of human mast cells by flow cytometry. In: J. Robinson, Z. Darzynkiewicz, P. Dean, A. Orfao, P. Rabinovich and L. Wheeless, eds. <i>Curr Protoc Cytom.</i> New York: John Wiley &amp; Sons, Inc; 2001; Chapter 6: Unit 6.6. <a target=xrefwindow id=d6336e2335 href="http://www.ncbi.nlm.nih.gov/pubmed/18770717">PubMed Abstract </a> | <a target=xrefwindow id=d6336e2338 href="http://dx.doi.org/10.1002/0471142956.cy0606s12">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d6336e2347 class=n-a></a>Escribano L, Diaz-Agustin B, L√≥pez A, <i> et al.</i>: Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). <i>Cytometry B Clin Cytom.</i> 2004; <b>58</b>(1): 1‚Äì8. <a target=xrefwindow id=d6336e2358 href="http://www.ncbi.nlm.nih.gov/pubmed/14994369">PubMed Abstract </a> | <a target=xrefwindow id=d6336e2361 href="http://dx.doi.org/10.1002/cyto.b.10072">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d6336e2370 class=n-a></a>Teodosio C, Garc√≠a-Montero AC, Jara-Acevedo M, <i> et al.</i>: Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. <i>J Allergy Clin Immunol.</i> 2010; <b>125</b>(3): 719‚Äì26, 726.e1‚Äì726.e4. <a target=xrefwindow id=d6336e2381 href="http://www.ncbi.nlm.nih.gov/pubmed/20061010">PubMed Abstract </a> | <a target=xrefwindow id=d6336e2384 href="http://dx.doi.org/10.1016/j.jaci.2009.10.020">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d6336e2393 class=n-a></a>Garcia-Montero AC, Jara-Acevedo M, Teodosio C, <i> et al.</i>: <i>KIT</i> mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. <i>Blood.</i> 2006; <b>108</b>(7): 2366‚Äì72. <a target=xrefwindow id=d6336e2407 href="http://www.ncbi.nlm.nih.gov/pubmed/16741248">PubMed Abstract </a> | <a target=xrefwindow id=d6336e2411 href="http://dx.doi.org/10.1182/blood-2006-04-015545">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d6336e2420 class=n-a></a>Kristensen T, Vestergaard H, M√∏ller MB: Improved detection of the <i>KIT</i> D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. <i>J Mol Diagn.</i> 2011; <b>13</b>(2): 180‚Äì8. <a target=xrefwindow id=d6336e2431 href="http://www.ncbi.nlm.nih.gov/pubmed/21354053">PubMed Abstract </a> | <a target=xrefwindow id=d6336e2434 href="http://dx.doi.org/10.1016/j.jmoldx.2010.10.004">Publisher Full Text </a> | <a target=xrefwindow id=d6336e2438 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3279709">Free Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718243776"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6336e2447 class=n-a></a>Kristensen T, Vestergaard H, Bindslev-Jensen C, <i> et al.</i>: Sensitive <i>KIT</i> D816V mutation analysis of blood as a diagnostic test in mastocytosis. <i>Am J Hematol.</i> 2014; <b>89</b>(5): 493‚Äì8. <a target=xrefwindow id=d6336e2461 href="http://www.ncbi.nlm.nih.gov/pubmed/24443360">PubMed Abstract </a> | <a target=xrefwindow id=d6336e2465 href="http://dx.doi.org/10.1002/ajh.23672">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718243776">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d6336e2479 class=n-a></a>Jara-Acevedo M, Teodosio C, Sanchez-Mu√±oz L, <i> et al.</i>: Detection of the <i>KIT</i> D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications. <i>Mod Pathol.</i> 2015; <b>28</b>(8): 1138‚Äì49. <a target=xrefwindow id=d6336e2493 href="http://www.ncbi.nlm.nih.gov/pubmed/26067933">PubMed Abstract </a> | <a target=xrefwindow id=d6336e2497 href="http://dx.doi.org/10.1038/modpathol.2015.72">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d6336e2506 class=n-a></a>Escribano L, Garcia-Montero A, Sanchez-Mu√±oz L, <i> et al.</i>: Diagnosis of Adult Mastocytosis: Role for Bone Marrow Analysis. In: K. Kottke-Marchant and B. Davis, eds. <i>Laboratory Hematology Practice</i>. London: Wiley-Blackwell; 2012; 388‚Äì98. <a target=xrefwindow id=d6336e2514 href="http://dx.doi.org/10.1002/9781444398595.ch29">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d6336e2523 class=n-a></a>Gonz√°lez-de-Olano D, Alvarez-Twose I, Vega A, <i> et al.</i>: Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis. <i>Immunotherapy.</i> 2011; <b>3</b>(5): 637‚Äì51. <a target=xrefwindow id=d6336e2534 href="http://www.ncbi.nlm.nih.gov/pubmed/21554093">PubMed Abstract </a> | <a target=xrefwindow id=d6336e2537 href="http://dx.doi.org/10.2217/imt.11.44">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d6336e2546 class=n-a></a>Escribano L, Orfao A, Villarrubia J, <i> et al.</i>: Sequential immunophenotypic analysis of mast cells in a case of systemic mast cell disease evolving to a mast cell leukemia. <i>Cytometry.</i> 1997; <b>30</b>(2): 98‚Äì102. <a target=xrefwindow id=d6336e2557 href="http://www.ncbi.nlm.nih.gov/pubmed/9149916">PubMed Abstract </a> | <a target="xrefwindow" id="d6336e2560" href="http://dx.doi.org/10.1002/(SICI)1097-0320(19970415)30:2<98::AID-CYTO4&gt;3.0.CO;2-9">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d6336e2569 class=n-a></a>S√°nchez-Mu√±oz L, Morgado JM, √Ålvarez-Twose I, <i> et al.</i>: Diagnosis and classification of mastocytosis in non-specialized <i>versus</i> reference centres: a Spanish Network on Mastocytosis (REMA) study on 122 patients. <i>Br J Haematol.</i> 2016; <b>172</b>(1): 56‚Äì63. <a target=xrefwindow id=d6336e2583 href="http://www.ncbi.nlm.nih.gov/pubmed/26456532">PubMed Abstract </a> | <a target=xrefwindow id=d6336e2587 href="http://dx.doi.org/10.1111/bjh.13789">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d6336e2596 class=n-a></a>Valent P, Akin C, Arock M, <i> et al.</i>: Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. <i>Int Arch Allergy Immunol.</i> 2012; <b>157</b>(3): 215‚Äì25. <a target=xrefwindow id=d6336e2607 href="http://www.ncbi.nlm.nih.gov/pubmed/22041891">PubMed Abstract </a> | <a target=xrefwindow id=d6336e2610 href="http://dx.doi.org/10.1159/000328760">Publisher Full Text </a> | <a target=xrefwindow id=d6336e2614 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3224511">Free Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726910129"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6336e2624 class=n-a></a>Cardet JC, Castells MC, Hamilton MJ: Immunology and clinical manifestations of non-clonal mast cell activation syndrome. <i>Curr Allergy Asthma Rep.</i> 2013; <b>13</b>(1): 10‚Äì8. <a target=xrefwindow id=d6336e2632 href="http://www.ncbi.nlm.nih.gov/pubmed/23212667">PubMed Abstract </a> | <a target=xrefwindow id=d6336e2635 href="http://dx.doi.org/10.1007/s11882-012-0326-8">Publisher Full Text </a> | <a target=xrefwindow id=d6336e2638 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3545645">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726910129">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d6336e2651 class=n-a></a>Matito A, Alvarez-Twose I, Morgado JM, <i> et al.</i>: Anaphylaxis as a clinical manifestation of clonal mast cell disorders. <i>Curr Allergy Asthma Rep.</i> 2014; <b>14</b>(8): 450. <a target=xrefwindow id=d6336e2662 href="http://www.ncbi.nlm.nih.gov/pubmed/24947681">PubMed Abstract </a> | <a target=xrefwindow id=d6336e2665 href="http://dx.doi.org/10.1007/s11882-014-0450-8">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d6336e2674 class=n-a></a>Valent P, Escribano L, Broesby-Olsen S, <i> et al.</i>: Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. <i>Allergy.</i> 2014; <b>69</b>(10): 1267‚Äì74. <a target=xrefwindow id=d6336e2685 href="http://www.ncbi.nlm.nih.gov/pubmed/24836395">PubMed Abstract </a> | <a target=xrefwindow id=d6336e2688 href="http://dx.doi.org/10.1111/all.12436">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d6336e2697 class=n-a></a>Brockow K, Jofer C, Behrendt H, <i> et al.</i>: Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. <i>Allergy.</i> 2008; <b>63</b>(2): 226‚Äì32. <a target=xrefwindow id=d6336e2708 href="http://www.ncbi.nlm.nih.gov/pubmed/18186813">PubMed Abstract </a> | <a target=xrefwindow id=d6336e2711 href="http://dx.doi.org/10.1111/j.1398-9995.2007.01569.x">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d6336e2720 class=n-a></a>Gonz√°lez de Olano D, de la Hoz Caballer B, N√∫√±ez L√≥pez R, <i> et al.</i>: Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). <i>Clin Exp Allergy.</i> 2007; <b>37</b>(10): 1547‚Äì55. <a target=xrefwindow id=d6336e2731 href="http://www.ncbi.nlm.nih.gov/pubmed/17883734">PubMed Abstract </a> | <a target=xrefwindow id=d6336e2734 href="http://dx.doi.org/10.1111/j.1365-2222.2007.02804.x">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d6336e2743 class=n-a></a>Alvarez-Twose I, Gonz√°lez de Olano D, S√°nchez-Mu√±oz L, <i> et al.</i>: Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. <i>J Allergy Clin Immunol.</i> 2010; <b>125</b>(6): 1269‚Äì1278.e2. <a target=xrefwindow id=d6336e2754 href="http://www.ncbi.nlm.nih.gov/pubmed/20434205">PubMed Abstract </a> | <a target=xrefwindow id=d6336e2757 href="http://dx.doi.org/10.1016/j.jaci.2010.02.019">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1160956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6336e2767 class=n-a></a>Bonadonna P, Perbellini O, Passalacqua G, <i> et al.</i>: Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. <i>J Allergy Clin Immunol.</i> 2009; <b>123</b>(3): 680‚Äì6. <a target=xrefwindow id=d6336e2778 href="http://www.ncbi.nlm.nih.gov/pubmed/19135713">PubMed Abstract </a> | <a target=xrefwindow id=d6336e2781 href="http://dx.doi.org/10.1016/j.jaci.2008.11.018">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1160956">F1000 Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d6336e2794 class=n-a></a>Sperr WR, Escribano L, Jordan JH, <i> et al.</i>: Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. <i>Leuk Res.</i> 2001; <b>25</b>(7): 529‚Äì36. <a target=xrefwindow id=d6336e2805 href="http://www.ncbi.nlm.nih.gov/pubmed/11377677">PubMed Abstract </a> | <a target=xrefwindow id=d6336e2808 href="http://dx.doi.org/10.1016/S0145-2126(01)00041-8">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d6336e2817 class=n-a></a>Horny HP, Sillaber C, Menke D, <i> et al.</i>: Diagnostic value of immunostaining for tryptase in patients with mastocytosis. <i>Am J Surg Pathol.</i> 1998; <b>22</b>(9): 1132‚Äì40. <a target=xrefwindow id=d6336e2828 href="http://www.ncbi.nlm.nih.gov/pubmed/9737247">PubMed Abstract </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d6336e2837 class=n-a></a>Horny HP, Valent P: Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. <i>Leuk Res.</i> 2001; <b>25</b>(7): 543‚Äì51. <a target=xrefwindow id=d6336e2845 href="http://www.ncbi.nlm.nih.gov/pubmed/11377679">PubMed Abstract </a> | <a target=xrefwindow id=d6336e2848 href="http://dx.doi.org/10.1016/S0145-2126(01)00021-2">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d6336e2857 class=n-a></a>Escribano L, Orfao A, D√≠az-Agustin B, <i> et al.</i>: Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. <i>Blood.</i> 1998; <b>91</b>(8): 2731‚Äì6. <a target=xrefwindow id=d6336e2868 href="http://www.ncbi.nlm.nih.gov/pubmed/9531582">PubMed Abstract </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1012550"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6336e2877 class=n-a></a>Sotlar K, Escribano L, Landt O, <i> et al.</i>: One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. <i>Am J Pathol.</i> 2003; <b>162</b>(3): 737‚Äì46. <a target=xrefwindow id=d6336e2888 href="http://www.ncbi.nlm.nih.gov/pubmed/12598308">PubMed Abstract </a> | <a target=xrefwindow id=d6336e2891 href="http://dx.doi.org/10.1016/S0002-9440(10)63870-9">Publisher Full Text </a> | <a target=xrefwindow id=d6336e2895 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1868096">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1012550">F1000 Recommendation</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d6336e2909 class=n-a></a>Alvarez-Twose I, Zanotti R, Gonz√°lez-de-Olano D, <i> et al.</i>: Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. <i>J Allergy Clin Immunol.</i> 2014; <b>133</b>(2): 520‚Äì8. <a target=xrefwindow id=d6336e2920 href="http://www.ncbi.nlm.nih.gov/pubmed/23921094">PubMed Abstract </a> | <a target=xrefwindow id=d6336e2923 href="http://dx.doi.org/10.1016/j.jaci.2013.06.020">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725314073"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6336e2932 class=n-a></a>De Matteis G, Zanotti R, Colarossi S, <i> et al.</i>: The impact of sensitive <i>KIT</i> D816V detection on recognition of indolent Systemic Mastocytosis. <i>Leuk Res.</i> 2015; <b>39</b>(3): 273‚Äì8. <a target=xrefwindow id=d6336e2946 href="http://www.ncbi.nlm.nih.gov/pubmed/25582384">PubMed Abstract </a> | <a target=xrefwindow id=d6336e2950 href="http://dx.doi.org/10.1016/j.leukres.2014.11.029">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725314073">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d6336e2963 class=n-a></a>Alvarez-Twose I, Matito A, S√°nchez-Mu√±oz L, <i> et al.</i>: Management of adult mastocytosis. <i>Expert Opin Orphan Drugs.</i> 2014; <b>2</b>(4): 321‚Äì36. <a target=xrefwindow id=d6336e2974 href="http://dx.doi.org/10.1517/21678707.2014.884922">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718363160"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6336e2983 class=n-a></a>Siebenhaar F, Akin C, Bindslev-Jensen C, <i> et al.</i>: Treatment strategies in mastocytosis. <i>Immunol Allergy Clin North Am.</i> 2014; <b>34</b>(2): 433‚Äì47. <a target=xrefwindow id=d6336e2994 href="http://www.ncbi.nlm.nih.gov/pubmed/24745685">PubMed Abstract </a> | <a target=xrefwindow id=d6336e2997 href="http://dx.doi.org/10.1016/j.iac.2014.01.012">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718363160">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725384341"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6336e3010 class=n-a></a>Arock M, Akin C, Hermine O, <i> et al.</i>: Current treatment options in patients with mastocytosis: status in 2015 and future perspectives. <i>Eur J Haematol.</i> 2015; <b>94</b>(6): 474‚Äì90. <a target=xrefwindow id=d6336e3021 href="http://www.ncbi.nlm.nih.gov/pubmed/25753531">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3024 href="http://dx.doi.org/10.1111/ejh.12544">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725384341">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d6336e3037 class=n-a></a>Okayama Y, Church MK: Comparison of the modulatory effect of ketotifen, sodium cromoglycate, procaterol and salbutamol in human skin, lung and tonsil mast cells. <i>Int Arch Allergy Immunol.</i> 1992; <b>97</b>(3): 216‚Äì25. <a target=xrefwindow id=d6336e3045 href="http://www.ncbi.nlm.nih.gov/pubmed/1375203">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3048 href="http://dx.doi.org/10.1159/000236122">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d6336e3058 class=n-a></a>Weller K, Maurer M: Desloratadine inhibits human skin mast cell activation and histamine release. <i>J Invest Dermatol.</i> 2009; <b>129</b>(11): 2723‚Äì6. <a target=xrefwindow id=d6336e3066 href="http://www.ncbi.nlm.nih.gov/pubmed/19516262">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3069 href="http://dx.doi.org/10.1038/jid.2009.134">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d6336e3078 class=n-a></a>Graves L 3rd, Stechschulte DJ, Morris DC, <i> et al.</i>: Inhibition of mediator release in systemic mastocytosis is associated with reversal of bone changes. <i>J Bone Miner Res.</i> 1990; <b>5</b>(11): 1113‚Äì9. <a target=xrefwindow id=d6336e3089 href="http://www.ncbi.nlm.nih.gov/pubmed/2270775">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3092 href="http://dx.doi.org/10.1002/jbmr.5650051104">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d6336e3101 class=n-a></a>P√≥voa P, Ducla-Soares J, Fernandes A, <i> et al.</i>: A case of systemic mastocytosis; therapeutic efficacy of ketotifen. <i>J Intern Med.</i> 1991; <b>229</b>(5): 475‚Äì7. <a target=xrefwindow id=d6336e3112 href="http://www.ncbi.nlm.nih.gov/pubmed/2040876">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3115 href="http://dx.doi.org/10.1111/j.1365-2796.1991.tb00379.x">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d6336e3124 class=n-a></a>Ting S: Ketotifen and systemic mastocytosis. <i>J Allergy Clin Immunol.</i> 1990; <b>85</b>(4): 818. <a target=xrefwindow id=d6336e3132 href="http://www.ncbi.nlm.nih.gov/pubmed/2324420">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3135 href="http://dx.doi.org/10.1016/0091-6749(90)90205-I">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d6336e3144 class=n-a></a>Escribano L, Akin C, Castells M, <i> et al.</i>: Current options in the treatment of mast cell mediator-related symptoms in mastocytosis. <i>Inflamm Allergy Drug Targets.</i> 2006; <b>5</b>(1): 61‚Äì77. <a target=xrefwindow id=d6336e3155 href="http://www.ncbi.nlm.nih.gov/pubmed/16613565">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3158 href="http://dx.doi.org/10.2174/187152806775269303">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d6336e3167 class=n-a></a>Siebenhaar F, F√∂rtsch A, Krause K, <i> et al.</i>: Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial. <i>Allergy.</i> 2013; <b>68</b>(7): 949‚Äì52. <a target=xrefwindow id=d6336e3178 href="http://www.ncbi.nlm.nih.gov/pubmed/23734572">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3181 href="http://dx.doi.org/10.1111/all.12159">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726910149"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6336e3191 class=n-a></a>Cardet JC, Akin C, Lee MJ: Mastocytosis: update on pharmacotherapy and future directions. <i>Expert Opin Pharmacother.</i> 2013; <b>14</b>(15): 2033‚Äì45. <a target=xrefwindow id=d6336e3199 href="http://www.ncbi.nlm.nih.gov/pubmed/24044484">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3202 href="http://dx.doi.org/10.1517/14656566.2013.824424">Publisher Full Text </a> | <a target=xrefwindow id=d6336e3205 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4362676">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726910149">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d6336e3218 class=n-a></a>Edwards A, Stepehen T: The Chromones: sodium cromolyn and nedocromil sodium. In: N.F. Adkinson, ed. <i>Middleton's allergy: principles and practice</i>. China: Mosby; 2009. </span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d6336e3230 class=n-a></a>Lester MR, Bratton DL: Adverse reactions to cromolyn sodium: patient report and review of the literature. <i>Clin Pediatr (Phila).</i> 1997; <b>36</b>(12): 707‚Äì10. <a target=xrefwindow id=d6336e3238 href="http://www.ncbi.nlm.nih.gov/pubmed/9415839">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3241 href="http://dx.doi.org/10.1177/000992289703601207">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d6336e3250 class=n-a></a>Edwards AM, Capkov√° S: Oral and topical sodium cromoglicate in the treatment of diffuse cutaneous mastocytosis in an infant. <i>BMJ Case Rep.</i> 2011; <b>2011</b>. pii: bcr0220113910. <a target=xrefwindow id=d6336e3258 href="http://www.ncbi.nlm.nih.gov/pubmed/22693187">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3261 href="http://dx.doi.org/10.1136/bcr.02.2011.3910">Publisher Full Text </a> | <a target=xrefwindow id=d6336e3264 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3128352">Free Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d6336e3273 class=n-a></a>Vieira Dos Santos R, Magerl M, Martus P, <i> et al.</i>: Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus. <i>Br J Dermatol.</i> 2010; <b>162</b>(3): 674‚Äì6. <a target=xrefwindow id=d6336e3284 href="http://www.ncbi.nlm.nih.gov/pubmed/19785618">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3287 href="http://dx.doi.org/10.1111/j.1365-2133.2009.09516.x">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d6336e3296 class=n-a></a>Bochenek G, Nizankowska E, Gielicz A, <i> et al.</i>: Plasma 9alpha,11beta-PGF2, a PGD2 metabolite, as a sensitive marker of mast cell activation by allergen in bronchial asthma. <i>Thorax.</i> 2004; <b>59</b>(6): 459‚Äì64. <a target=xrefwindow id=d6336e3307 href="http://www.ncbi.nlm.nih.gov/pubmed/15170023">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3310 href="http://dx.doi.org/10.1136/thx.2003.013573">Publisher Full Text </a> | <a target=xrefwindow id=d6336e3314 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1747024">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d6336e3324 class=n-a></a>Butterfield JH: Survey of aspirin administration in systemic mastocytosis. <i>Prostaglandins Other Lipid Mediat.</i> 2009; <b>88</b>(3‚Äì4): 122‚Äì4. <a target=xrefwindow id=d6336e3332 href="http://www.ncbi.nlm.nih.gov/pubmed/19429499">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3335 href="http://dx.doi.org/10.1016/j.prostaglandins.2009.01.001">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d6336e3344 class=n-a></a>Barton J, Lavker RM, Schechter NM, <i> et al.</i>: Treatment of urticaria pigmentosa with corticosteroids. <i>Arch Dermatol.</i> 1985; <b>121</b>(12): 1516‚Äì23. <a target=xrefwindow id=d6336e3355 href="http://www.ncbi.nlm.nih.gov/pubmed/4062333">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3358 href="http://dx.doi.org/10.1001/archderm.1985.01660120042017">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1137882"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6336e3367 class=n-a></a>Kaplan AP, Joseph K, Maykut RJ, <i> et al.</i>: Treatment of chronic autoimmune urticaria with omalizumab. <i>J Allergy Clin Immunol.</i> 2008; <b>122</b>(3): 569‚Äì73. <a target=xrefwindow id=d6336e3378 href="http://www.ncbi.nlm.nih.gov/pubmed/18774392">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3381 href="http://dx.doi.org/10.1016/j.jaci.2008.07.006">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1137882">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726002686"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6336e3394 class=n-a></a>Warrier P, Casale TB: Omalizumab in idiopathic anaphylaxis. <i>Ann Allergy Asthma Immunol.</i> 2009; <b>102</b>(3): 257‚Äì8. <a target=xrefwindow id=d6336e3402 href="http://www.ncbi.nlm.nih.gov/pubmed/19354075">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3405 href="http://dx.doi.org/10.1016/S1081-1206(10)60091-9">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726002686">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d6336e3418 class=n-a></a>Engler RJ, Davis WS: Rush Hymenoptera venom immunotherapy: successful treatment in a patient with systemic mast cell disease. <i>J Allergy Clin Immunol.</i> 1994; <b>94</b>(3 Pt 1): 556‚Äì9. <a target=xrefwindow id=d6336e3426 href="http://www.ncbi.nlm.nih.gov/pubmed/8083461">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3429 href="http://dx.doi.org/10.1016/0091-6749(94)90213-5">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d6336e3438 class=n-a></a>Fricker M, Helbling A, Schwartz L, <i> et al.</i>: Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. <i>J Allergy Clin Immunol.</i> 1997; <b>100</b>(1): 11‚Äì5. <a target=xrefwindow id=d6336e3449 href="http://www.ncbi.nlm.nih.gov/pubmed/9257781">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3452 href="http://dx.doi.org/10.1016/S0091-6749(97)70188-X">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d6336e3462 class=n-a></a>Haeberli G, Bronnimann M, Hunziker T, <i> et al.</i>: Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. <i>Clin Exp Allergy.</i> 2003; <b>33</b>(9): 1216‚Äì20. <a target=xrefwindow id=d6336e3473 href="http://www.ncbi.nlm.nih.gov/pubmed/12956741">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3476 href="http://dx.doi.org/10.1046/j.1365-2222.2003.01755.x">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d6336e3485 class=n-a></a>Bonadonna P, Zanotti R, Caruso B, <i> et al.</i>: Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and <i>Hymenoptera</i> allergy. <i>J Allergy Clin Immunol.</i> 2008; <b>121</b>(1): 256‚Äì7. <a target=xrefwindow id=d6336e3499 href="http://www.ncbi.nlm.nih.gov/pubmed/18206512">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3503 href="http://dx.doi.org/10.1016/j.jaci.2007.10.014">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d6336e3512 class=n-a></a>Gonz√°lez de Olano D, Alvarez-Twose I, Esteban-L√≥pez MI, <i> et al.</i>: Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. <i>J Allergy Clin Immunol.</i> 2008; <b>121</b>(2): 519‚Äì26. <a target=xrefwindow id=d6336e3523 href="http://www.ncbi.nlm.nih.gov/pubmed/18177694">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3526 href="http://dx.doi.org/10.1016/j.jaci.2007.11.010">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d6336e3535 class=n-a></a>Bonadonna P, Gonzalez-de-Olano D, Zanotti R, <i> et al.</i>: Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations. <i>J Allergy Clin Immunol Pract.</i> 2013; <b>1</b>(5): 474‚Äì8. <a target=xrefwindow id=d6336e3546 href="http://www.ncbi.nlm.nih.gov/pubmed/24565619">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3549 href="http://dx.doi.org/10.1016/j.jaip.2013.06.014">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d6336e3558 class=n-a></a>Kontou-Fili K, Filis CI: Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis. <i>Allergy.</i> 2009; <b>64</b>(9): 1384‚Äì5. <a target=xrefwindow id=d6336e3566 href="http://www.ncbi.nlm.nih.gov/pubmed/19432937">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3569 href="http://dx.doi.org/10.1111/j.1398-9995.2009.02045.x">Publisher Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d6336e3578 class=n-a></a>Dubois AE: Mastocytosis and Hymenoptera allergy. <i>Curr Opin Allergy Clin Immunol.</i> 2004; <b>4</b>(4): 291‚Äì5. <a target=xrefwindow id=d6336e3586 href="http://www.ncbi.nlm.nih.gov/pubmed/15238795">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3589 href="http://dx.doi.org/10.1097/01.all.0000136756.20701.f8">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d6336e3599 class=n-a></a>Oude Elberink JN, de Monchy JG, Kors JW, <i> et al.</i>: Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. <i>J Allergy Clin Immunol.</i> 1997; <b>99</b>(1 Pt 1): 153‚Äì4. <a target=xrefwindow id=d6336e3610 href="http://www.ncbi.nlm.nih.gov/pubmed/9003225">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3613 href="http://dx.doi.org/10.1016/S0091-6749(97)70314-2">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d6336e3622 class=n-a></a>Guhl S, Stefaniak R, Strathmann M, <i> et al.</i>: Bivalent effect of UV light on human skin mast cells-low-level mediator release at baseline but potent suppression upon mast cell triggering. <i>J Invest Dermatol.</i> 2005; <b>124</b>(2): 453‚Äì6. <a target=xrefwindow id=d6336e3633 href="http://www.ncbi.nlm.nih.gov/pubmed/15675967">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3636 href="http://dx.doi.org/10.1111/j.0022-202X.2004.23523.x">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d6336e3645 class=n-a></a>Guhl S, Hartmann K, Tapkenhinrichs S, <i> et al.</i>: Ultraviolet irradiation induces apoptosis in human immature, but not in skin mast cells. <i>J Invest Dermatol.</i> 2003; <b>121</b>(4): 837‚Äì44. <a target=xrefwindow id=d6336e3656 href="http://www.ncbi.nlm.nih.gov/pubmed/14632203">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3659 href="http://dx.doi.org/10.1046/j.1523-1747.2003.12480.x">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d6336e3668 class=n-a></a>Kronauer C, Eberlein-Konig B, Ring J, <i> et al.</i>: Influence of UVB, UVA and UVA1 irradiation on histamine release from human basophils and mast cells <i>in vitro</i> in the presence and absence of antioxidants. <i>Photochem Photobiol.</i> 2003; <b>77</b>(5): 531‚Äì4. <a target=xrefwindow id=d6336e3682 href="http://www.ncbi.nlm.nih.gov/pubmed/12812296">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3686 href="http://dx.doi.org/10.1562/0031-8655(2003)0770531IOUUAU2.0.CO2">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d6336e3695 class=n-a></a>Prignano F, Troiano M, Lotti T: Cutaneous mastocytosis: successful treatment with narrowband ultraviolet B phototherapy. <i>Clin Exp Dermatol.</i> 2010; <b>35</b>(8): 914‚Äì5. <a target=xrefwindow id=d6336e3703 href="http://www.ncbi.nlm.nih.gov/pubmed/20456394">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3706 href="http://dx.doi.org/10.1111/j.1365-2230.2010.03825.x">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718843541"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6336e3715 class=n-a></a>Brazzelli V, Grasso V, Manna G, <i> et al.</i>: Indolent systemic mastocytosis treated with narrow-band UVB phototherapy: study of five cases. <i>J Eur Acad Dermatol Venereol.</i> 2012; <b>26</b>(4): 465‚Äì9. <a target=xrefwindow id=d6336e3726 href="http://www.ncbi.nlm.nih.gov/pubmed/21564325">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3729 href="http://dx.doi.org/10.1111/j.1468-3083.2011.04098.x">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718843541">F1000 Recommendation</a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d6336e3743 class=n-a></a>Zandi S, Kalia S, Lui H: UVA1 phototherapy: a concise and practical review. <i>Skin Therapy Lett.</i> 2012; <b>17</b>(1): 1‚Äì4. <a target=xrefwindow id=d6336e3751 href="http://www.ncbi.nlm.nih.gov/pubmed/22358227">PubMed Abstract </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d6336e3760 class=n-a></a>Smith ML, Orton PW, Chu H, <i> et al.</i>: Photochemotherapy of dominant, diffuse, cutaneous mastocytosis. <i>Pediatr Dermatol.</i> 1990; <b>7</b>(4): 251‚Äì5. <a target=xrefwindow id=d6336e3771 href="http://www.ncbi.nlm.nih.gov/pubmed/2080117">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3774 href="http://dx.doi.org/10.1111/j.1525-1470.1990.tb01020.x">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d6336e3783 class=n-a></a>Manolagas SC, Jilka RL: Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. <i>N Engl J Med.</i> 1995; <b>332</b>(5): 305‚Äì11. <a target=xrefwindow id=d6336e3791 href="http://www.ncbi.nlm.nih.gov/pubmed/7816067">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3794 href="http://dx.doi.org/10.1056/NEJM199502023320506">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d6336e3803 class=n-a></a>Rabenhorst A, Christopeit B, Leja S, <i> et al.</i>: Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis. <i>J Allergy Clin Immunol.</i> 2013; <b>132</b>(5): 1234‚Äì1237.e7. <a target=xrefwindow id=d6336e3814 href="http://www.ncbi.nlm.nih.gov/pubmed/23910691">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3817 href="http://dx.doi.org/10.1016/j.jaci.2013.06.019">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d6336e3826 class=n-a></a>Lim AY, Ostor AJ, Love S, <i> et al.</i>: Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment. <i>Ann Rheum Dis.</i> 2005; <b>64</b>(6): 965‚Äì6. <a target=xrefwindow id=d6336e3837 href="http://www.ncbi.nlm.nih.gov/pubmed/15897317">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3840 href="http://dx.doi.org/10.1136/ard.2004.029116">Publisher Full Text </a> | <a target=xrefwindow id=d6336e3844 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1755523">Free Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d6336e3853 class=n-a></a>Rossini M, Zanotti R, Viapiana O, <i> et al.</i>: Bone involvement and osteoporosis in mastocytosis. <i>Immunol Allergy Clin North Am.</i> 2014; <b>34</b>(2): 383‚Äì96. <a target=xrefwindow id=d6336e3864 href="http://www.ncbi.nlm.nih.gov/pubmed/24745681">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3867 href="http://dx.doi.org/10.1016/j.iac.2014.01.011">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d6336e3877 class=n-a></a>Sall√©s M, Holgado S, Navarro JT, <i> et al.</i>: [Osteoporosis as a first manifestation of systemic mastocytosis. Study of 6 cases]. <i>Med Clin (Barc).</i> 2007; <b>128</b>(6): 216‚Äì8. <a target=xrefwindow id=d6336e3888 href="http://www.ncbi.nlm.nih.gov/pubmed/17335726">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3891 href="http://dx.doi.org/10.1016/S0025-7753(07)72541-1">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d6336e3900 class=n-a></a>Lehmann T, Beyeler C, L√§mmle B, <i> et al.</i>: Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B. <i>Br J Rheumatol.</i> 1996; <b>35</b>(9): 898‚Äì900. <a target=xrefwindow id=d6336e3911 href="http://www.ncbi.nlm.nih.gov/pubmed/8810675">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3914 href="http://dx.doi.org/10.1093/rheumatology/35.9.898">Publisher Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d6336e3923 class=n-a></a>Weide R, Ehlenz K, Lorenz W, <i> et al.</i>: Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. <i>Ann Hematol.</i> 1996; <b>72</b>(1): 41‚Äì3. <a target=xrefwindow id=d6336e3934 href="http://www.ncbi.nlm.nih.gov/pubmed/8605279">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3937 href="http://dx.doi.org/10.1007/BF00663015">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725281360"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6336e3946 class=n-a></a>McNeil BD, Pundir P, Meeker S, <i> et al.</i>: Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. <i>Nature.</i> 2015; <b>519</b>(7542): 237‚Äì41. <a target=xrefwindow id=d6336e3957 href="http://www.ncbi.nlm.nih.gov/pubmed/25517090">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3960 href="http://dx.doi.org/10.1038/nature14022">Publisher Full Text </a> | <a target=xrefwindow id=d6336e3964 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4359082">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725281360">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d6336e3977 class=n-a></a>Nautiyal KM, Ribeiro AC, Pfaff DW, <i> et al.</i>: Brain mast cells link the immune system to anxiety-like behavior. <i>Proc Natl Acad Sci U S A.</i> 2008; <b>105</b>(46): 18053‚Äì7. <a target=xrefwindow id=d6336e3988 href="http://www.ncbi.nlm.nih.gov/pubmed/19004805">PubMed Abstract </a> | <a target=xrefwindow id=d6336e3991 href="http://dx.doi.org/10.1073/pnas.0809479105">Publisher Full Text </a> | <a target=xrefwindow id=d6336e3995 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2584714">Free Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726910168"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6336e4004 class=n-a></a>Nautiyal KM, Dailey CA, Jahn JL, <i> et al.</i>: Serotonin of mast cell origin contributes to hippocampal function. <i>Eur J Neurosci.</i> 2012; <b>36</b>(3): 2347‚Äì59. <a target=xrefwindow id=d6336e4015 href="http://www.ncbi.nlm.nih.gov/pubmed/22632453">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4018 href="http://dx.doi.org/10.1111/j.1460-9568.2012.08138.x">Publisher Full Text </a> | <a target=xrefwindow id=d6336e4022 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3721752">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726910168">F1000 Recommendation</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/5952957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6336e4036 class=n-a></a>Hannestad J, DellaGioia N, Ortiz N, <i> et al.</i>: Citalopram reduces endotoxin-induced fatigue. <i>Brain Behav Immun.</i> 2011; <b>25</b>(2): 256‚Äì9. <a target=xrefwindow id=d6336e4047 href="http://www.ncbi.nlm.nih.gov/pubmed/20955776">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4050 href="http://dx.doi.org/10.1016/j.bbi.2010.10.013">Publisher Full Text </a> | <a target=xrefwindow id=d6336e4054 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3025065">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/5952957">F1000 Recommendation</a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d6336e4067 class=n-a></a>Moura DS, Georgin-Lavialle S, Gaillard R, <i> et al.</i>: Neuropsychological features of adult mastocytosis. <i>Immunol Allergy Clin North Am.</i> 2014; <b>34</b>(2): 407‚Äì22. <a target=xrefwindow id=d6336e4078 href="http://www.ncbi.nlm.nih.gov/pubmed/24745683">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4081 href="http://dx.doi.org/10.1016/j.iac.2014.02.001">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d6336e4090 class=n-a></a>Worobec AS, Akin C, Scott LM, <i> et al.</i>: Mastocytosis complicating pregnancy. <i>Obstet Gynecol.</i> 2000; <b>95</b>(3): 391‚Äì5. <a target=xrefwindow id=d6336e4101 href="http://www.ncbi.nlm.nih.gov/pubmed/10711550">PubMed Abstract </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d6336e4110 class=n-a></a>Matito A, √Ålvarez-Twose I, Morgado JM, <i> et al.</i>: Clinical impact of pregnancy in mastocytosis: a study of the Spanish Network on Mastocytosis (REMA) in 45 cases. <i>Int Arch Allergy Immunol.</i> 2011; <b>156</b>(1): 104‚Äì11. <a target=xrefwindow id=d6336e4121 href="http://www.ncbi.nlm.nih.gov/pubmed/21447966">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4124 href="http://dx.doi.org/10.1159/000321954">Publisher Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d6336e4133 class=n-a></a>Hartmann K, Escribano L, Grattan C, <i> et al.</i>: Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma &amp; Immunology; and the European Academy of Allergology and Clinical Immunology. <i>J Allergy Clin Immunol.</i> 2016; <b>137</b>(1): 35‚Äì45. <a target=xrefwindow id=d6336e4144 href="http://www.ncbi.nlm.nih.gov/pubmed/26476479">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4147 href="http://dx.doi.org/10.1016/j.jaci.2015.08.034">Publisher Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d6336e4156 class=n-a></a>S√°nchez-Matas I, Matito A, Gonzalez de Olano D, <i> et al.</i>: Prevalence of hypersensitivity reactions to nonsteroidal anti-inflamatory drugs in 212 patients with mastocytosis in Spain. <i>Allergy.</i> 2009; <b>64</b>(Suppl 90): 551‚Äì598. <a target=xrefwindow id=d6336e4167 href="http://dx.doi.org/10.1111/j.1398-9995.2009.02078.x">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d6336e4177 class=n-a></a>Matito A, Morgado JM, S√°nchez-L√≥pez P, <i> et al.</i>: Management of Anesthesia in Adult and Pediatric Mastocytosis: A Study of the Spanish Network on Mastocytosis (REMA) Based on 726 Anesthetic Procedures. <i>Int Arch Allergy Immunol.</i> 2015; <b>167</b>(1): 47‚Äì56. <a target=xrefwindow id=d6336e4188 href="http://www.ncbi.nlm.nih.gov/pubmed/26160029">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4191 href="http://dx.doi.org/10.1159/000436969">Publisher Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d6336e4200 class=n-a></a>Carter MC, Uzzaman A, Scott LM, <i> et al.</i>: Pediatric mastocytosis: routine anesthetic management for a complex disease. <i>Anesth Analg.</i> 2008; <b>107</b>(2): 422‚Äì7. <a target=xrefwindow id=d6336e4211 href="http://www.ncbi.nlm.nih.gov/pubmed/18633019">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4214 href="http://dx.doi.org/10.1213/ane.0b013e31817e6d7c">Publisher Full Text </a> | <a target=xrefwindow id=d6336e4218 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2736554">Free Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d6336e4227 class=n-a></a>Ahmad N, Evans P, Lloyd-Thomas AR: Anesthesia in children with mastocytosis--a case based review. <i>Paediatr Anaesth.</i> 2009; <b>19</b>(2): 97‚Äì107. <a target=xrefwindow id=d6336e4235 href="http://www.ncbi.nlm.nih.gov/pubmed/19207896">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4238 href="http://dx.doi.org/10.1111/j.1460-9592.2008.02904.x">Publisher Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d6336e4247 class=n-a></a>Escribano L, Orfao A: Anaphylaxis in mastocytosis. In: M. Castells, ed. <i>Anaphylaxis and Hypersensitivity Reactions: From Molecular Markers to Rapid Desensitization</i>. New York; Humana Press, 2011; (1): 257‚Äì269. <a target=xrefwindow id=d6336e4252 href="http://dx.doi.org/10.1007/978-1-60327-951-2_16">Publisher Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d6336e4261 class=n-a></a>Bankova LG, Walter JE, Iyengar SR, <i> et al.</i>: Generalized bullous eruption after routine vaccination in a child with diffuse cutaneous mastocytosis. <i>J Allergy Clin Immunol Pract.</i> 2013; <b>1</b>(1): 94‚Äì6. <a target=xrefwindow id=d6336e4272 href="http://www.ncbi.nlm.nih.gov/pubmed/24229828">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4275 href="http://dx.doi.org/10.1016/j.jaip.2012.08.008">Publisher Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d6336e4284 class=n-a></a>Matito A, Bartolom√©-Zavala B, Alvarez-Twose I, <i> et al.</i>: IgE-mediated anaphylaxis to <i>Hippobosca equina</i> in a patient with systemic mastocytosis. <i>Allergy.</i> 2010; <b>65</b>(8): 1058‚Äì9. <a target=xrefwindow id=d6336e4298 href="http://www.ncbi.nlm.nih.gov/pubmed/20002662">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4302 href="http://dx.doi.org/10.1111/j.1398-9995.2009.02270.x">Publisher Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d6336e4312 class=n-a></a>Reiter N, Reiter M, Altrichter S, <i> et al.</i>: Anaphylaxis caused by mosquito allergy in systemic mastocytosis. <i>Lancet.</i> 2013; <b>382</b>(9901): 1380. <a target=xrefwindow id=d6336e4323 href="http://www.ncbi.nlm.nih.gov/pubmed/24139121">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4326 href="http://dx.doi.org/10.1016/S0140-6736(13)61605-0">Publisher Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d6336e4335 class=n-a></a>Gonzalez de Olano D, Alvarez-Twose I, Castells M, <i> et al.</i>: S√≠ndromes de activaci√≥n mastocitaria. In: IJ D√°vila Gonz√°lez, I J√°uregui Presa, JM Olaguible Rivera and JM Zubeldia, eds. <i>Tratado de Alergolog√≠a</i>. 2 ed. Madrid: Ergon; 2016; (4): 1316‚Äì1330. </span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d6336e4350 class=n-a></a>Escribano L, Akin C, Castells M, <i> et al.</i>: Mastocytosis: current concepts in diagnosis and treatment. <i>Ann Hematol.</i> 2002; <b>81</b>(12): 677‚Äì90. <a target=xrefwindow id=d6336e4361 href="http://www.ncbi.nlm.nih.gov/pubmed/12483363">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4364 href="http://dx.doi.org/10.1007/s00277-002-0575-z">Publisher Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d6336e4373 class=n-a></a>Worobec AS, Metcalfe DD: Mastocytosis: current treatment concepts. <i>Int Arch Allergy Immunol.</i> 2002; <b>127</b>(2): 153‚Äì5. <a target=xrefwindow id=d6336e4381 href="http://www.ncbi.nlm.nih.gov/pubmed/11919428">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4384 href="http://dx.doi.org/10.1159/000048189">Publisher Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d6336e4393 class=n-a></a>Hirschowitz BI, Groarke JF: Effect of cimetidine on gastric hypersecretion and diarrhea in systemic mastocytosis. <i>Ann Intern Med.</i> 1979; <b>90</b>(5): 769‚Äì71. <a target=xrefwindow id=d6336e4401 href="http://www.ncbi.nlm.nih.gov/pubmed/373561">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4404 href="http://dx.doi.org/10.7326/0003-4819-90-5-769">Publisher Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d6336e4413 class=n-a></a>Gasior-Chrzan B, Falk ES: Systemic mastocytosis treated with histamine H<sub>1</sub> and H<sub>2</sub> receptor antagonists. <i>Dermatology.</i> 1992; <b>184</b>(2): 149‚Äì52. <a target=xrefwindow id=d6336e4427 href="http://www.ncbi.nlm.nih.gov/pubmed/1498379">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4431 href="http://dx.doi.org/10.1159/000247526">Publisher Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d6336e4441 class=n-a></a>Dolovich J, Punthakee ND, MacMillan AB, <i> et al.</i>: Systemic mastocytosis: control of lifelong diarrhea by ingested disodium cromoglycate. <i>Can Med Assoc J.</i> 1974; <b>111</b>(7): 684‚Äì5. <a target=xrefwindow id=d6336e4452 href="http://www.ncbi.nlm.nih.gov/pubmed/4213416">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4455 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1947871">Free Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d6336e4464 class=n-a></a>Soter NA, Austen KF, Wasserman SI: Oral disodium cromoglycate in the treatment of systemic mastocytosis. <i>N Engl J Med.</i> 1979; <b>301</b>(9): 465‚Äì9. <a target=xrefwindow id=d6336e4472 href="http://www.ncbi.nlm.nih.gov/pubmed/111124">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4475 href="http://dx.doi.org/10.1056/NEJM197908303010903">Publisher Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d6336e4484 class=n-a></a>Czarnetzki BM, Behrendt H: Urticaria pigmentosa: clinical picture and response to oral disodium cromoglycate. <i>Br J Dermatol.</i> 1981; <b>105</b>(5): 563‚Äì7. <a target=xrefwindow id=d6336e4492 href="http://www.ncbi.nlm.nih.gov/pubmed/6794592">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4495 href="http://dx.doi.org/10.1111/j.1365-2133.1981.tb00800.x">Publisher Full Text </a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d6336e4504 class=n-a></a>Welch EA, Alper JC, Bogaars H, <i> et al.</i>: Treatment of bullous mastocytosis with disodium cromoglycate. <i>J Am Acad Dermatol.</i> 1983; <b>9</b>(3): 349‚Äì53. <a target=xrefwindow id=d6336e4515 href="http://www.ncbi.nlm.nih.gov/pubmed/6415132">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4518 href="http://dx.doi.org/10.1016/S0190-9622(83)70140-4">Publisher Full Text </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d6336e4527 class=n-a></a>Lindskov R, Lange Wantzin G, Knudsen L, <i> et al.</i>: Urticaria pigmentosa treated with oral disodium cromoglycate. <i>Dermatologica.</i> 1984; <b>169</b>(1): 49‚Äì52. <a target=xrefwindow id=d6336e4538 href="http://www.ncbi.nlm.nih.gov/pubmed/6432596">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4541 href="http://dx.doi.org/10.1159/000249567">Publisher Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d6336e4550 class=n-a></a>Alexander RR: Disodium cromoglycate in the treatment of systemic mastocytosis involving only bone. <i>Acta Haematol.</i> 1985; <b>74</b>(2): 108‚Äì10. <a target=xrefwindow id=d6336e4558 href="http://www.ncbi.nlm.nih.gov/pubmed/3937412">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4561 href="http://dx.doi.org/10.1159/000206179">Publisher Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d6336e4571 class=n-a></a>Rogers MP, Bloomingdale K, Murawski BJ, <i> et al.</i>: Mixed organic brain syndrome as a manifestation of systemic mastocytosis. <i>Psychosom Med.</i> 1986; <b>48</b>(6): 437‚Äì47. <a target=xrefwindow id=d6336e4582 href="http://www.ncbi.nlm.nih.gov/pubmed/3749421">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4585 href="http://dx.doi.org/10.1097/00006842-198607000-00006">Publisher Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d6336e4594 class=n-a></a>Leaf FA, Jaecks EP, Rodriguez DR: Bullous urticaria pigmentosa. <i>Cutis.</i> 1996; <b>58</b>(5): 358‚Äì60. <a target=xrefwindow id=d6336e4602 href="http://www.ncbi.nlm.nih.gov/pubmed/8934078">PubMed Abstract </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d6336e4611 class=n-a></a>Horan RF, Sheffer AL, Austen KF: Cromolyn sodium in the management of systemic mastocytosis. <i>J Allergy Clin Immunol.</i> 1990; <b>85</b>(5): 852‚Äì5. <a target=xrefwindow id=d6336e4619 href="http://www.ncbi.nlm.nih.gov/pubmed/2110198">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4622 href="http://dx.doi.org/10.1016/0091-6749(90)90067-E">Publisher Full Text </a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d6336e4631 class=n-a></a>Metcalfe DD: The treatment of mastocytosis: an overview. <i>J Invest Dermatol.</i> 1991; <b>96</b>(3): 55S‚Äì56S; discussion 56S‚Äì59S. <a target=xrefwindow id=d6336e4639 href="http://www.ncbi.nlm.nih.gov/pubmed/2002266">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4642 href="http://dx.doi.org/10.1111/1523-1747.ep12469049">Publisher Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d6336e4651 class=n-a></a>Martin MW, O'Sullivan AJ, Gomperts BD: Inhibition by cromoglycate and some flavonoids of nucleoside diphosphate kinase and of exocytosis from permeabilized mast cells. <i>Br J Pharmacol.</i> 1995; <b>115</b>(6): 1080‚Äì6. <a target=xrefwindow id=d6336e4659 href="http://www.ncbi.nlm.nih.gov/pubmed/7582506">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4662 href="http://dx.doi.org/10.1111/j.1476-5381.1995.tb15921.x">Publisher Full Text </a> | <a target=xrefwindow id=d6336e4665 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1909018">Free Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d6336e4674 class=n-a></a>Norris AA: Pharmacology of sodium cromoglycate. <i>Clin Exp Allergy.</i> 1996; <b>26</b>(Suppl 4): 5‚Äì7. <a target=xrefwindow id=d6336e4682 href="http://www.ncbi.nlm.nih.gov/pubmed/8809432">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4685 href="http://dx.doi.org/10.1111/j.1365-2222.1996.tb00661.x">Publisher Full Text </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a name=d6336e4695 class=n-a></a>Moreno-Borque R, Matito A, √Ålvarez-Twose I, <i> et al.</i>: Response to celecoxib in a patient with indolent systemic mastocytosis presenting with intractable diarrhea. <i>Ann Allergy Asthma Immunol.</i> 2015; <b>115</b>(5): 456‚Äì7. <a target=xrefwindow id=d6336e4706 href="http://www.ncbi.nlm.nih.gov/pubmed/26505934">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4709 href="http://dx.doi.org/10.1016/j.anai.2015.08.016">Publisher Full Text </a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a name=d6336e4718 class=n-a></a>Sancho-Chust JN, Chiner E, Camarasa A, <i> et al.</i>: Recent-onset bronchial asthma as a manifestation of systemic mastocytosis. <i>J Investig Allergol Clin Immunol.</i> 2009; <b>19</b>(6): 513‚Äì5. <a target=xrefwindow id=d6336e4729 href="http://www.ncbi.nlm.nih.gov/pubmed/20128434">PubMed Abstract </a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a name=d6336e4738 class=n-a></a>Tolar J, Tope WD, Neglia JP: Leukotriene-receptor inhibition for the treatment of systemic mastocytosis. <i>N Engl J Med.</i> 2004; <b>350</b>(7): 735‚Äì6. <a target=xrefwindow id=d6336e4746 href="http://www.ncbi.nlm.nih.gov/pubmed/14960756">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4749 href="http://dx.doi.org/10.1056/NEJM200402123500723">Publisher Full Text </a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a name=d6336e4758 class=n-a></a>Turner PJ, Kemp AS, Rogers M, <i> et al.</i>: Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis. <i>Pediatr Dermatol.</i> 2012; <b>29</b>(2): 222‚Äì3. <a target=xrefwindow id=d6336e4769 href="http://www.ncbi.nlm.nih.gov/pubmed/22044360">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4772 href="http://dx.doi.org/10.1111/j.1525-1470.2011.01576.x">Publisher Full Text </a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d6336e4781 class=n-a></a>Hauswirth AW, Simonitsch-Klupp I, Uffmann M, <i> et al.</i>: Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. <i>Leuk Res.</i> 2004; <b>28</b>(3): 249‚Äì57. <a target=xrefwindow id=d6336e4792 href="http://www.ncbi.nlm.nih.gov/pubmed/14687620">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4795 href="http://dx.doi.org/10.1016/S0145-2126(03)00259-5">Publisher Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d6336e4804 class=n-a></a>Matito A, Morgado JM, √Ålvarez-Twose I, <i> et al.</i>: Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome. <i>PLoS One.</i> 2013; <b>8</b>(10): e76116. <a target=xrefwindow id=d6336e4815 href="http://www.ncbi.nlm.nih.gov/pubmed/24155887">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4818 href="http://dx.doi.org/10.1371/journal.pone.0076116">Publisher Full Text </a> | <a target=xrefwindow id=d6336e4822 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3796517">Free Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718013537"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6336e4832 class=n-a></a>Oppong E, Flink N, Cato AC: Molecular mechanisms of glucocorticoid action in mast cells. <i>Mol Cell Endocrinol.</i> 2013; <b>380</b>(1‚Äì2): 119‚Äì26. <a target=xrefwindow id=d6336e4840 href="http://www.ncbi.nlm.nih.gov/pubmed/23707629">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4843 href="http://dx.doi.org/10.1016/j.mce.2013.05.014">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718013537">F1000 Recommendation</a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d6336e4856 class=n-a></a>Siebenhaar F, K√ºhn W, Zuberbier T, <i> et al.</i>: Successful treatment of cutaneous mastocytosis and M√©ni√®re disease with anti-IgE therapy. <i>J Allergy Clin Immunol.</i> 2007; <b>120</b>(1): 213‚Äì5. <a target=xrefwindow id=d6336e4867 href="http://www.ncbi.nlm.nih.gov/pubmed/17544095">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4870 href="http://dx.doi.org/10.1016/j.jaci.2007.05.011">Publisher Full Text </a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d6336e4879 class=n-a></a>Matito A, Bl√°zquez-Go√±i C, Morgado JM, <i> et al.</i>: Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis. <i>Ann Allergy Asthma Immunol.</i> 2013; <b>111</b>(5): 425‚Äì6. <a target=xrefwindow id=d6336e4890 href="http://www.ncbi.nlm.nih.gov/pubmed/24125156">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4893 href="http://dx.doi.org/10.1016/j.anai.2013.08.014">Publisher Full Text </a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726910185"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6336e4902 class=n-a></a>Sokol KC, Ghazi A, Kelly BC, <i> et al.</i>: Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report. <i>J Allergy Clin Immunol Pract.</i> 2014; <b>2</b>(3): 266‚Äì70. <a target=xrefwindow id=d6336e4913 href="http://www.ncbi.nlm.nih.gov/pubmed/24811015">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4916 href="http://dx.doi.org/10.1016/j.jaip.2014.03.009">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726910185">F1000 Recommendation</a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a name=d6336e4929 class=n-a></a>Carter MC, Robyn JA, Bressler PB, <i> et al.</i>: Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. <i>J Allergy Clin Immunol.</i> 2007; <b>119</b>(6): 1550‚Äì1. <a target=xrefwindow id=d6336e4940 href="http://www.ncbi.nlm.nih.gov/pubmed/17481708">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4943 href="http://dx.doi.org/10.1016/j.jaci.2007.03.032">Publisher Full Text </a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726910190"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6336e4952 class=n-a></a>Lieberoth S, Thomsen SF: Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab. <i>Case Rep Med.</i> 2015; <b>2015</b>: 903541. <a target=xrefwindow id=d6336e4960 href="http://www.ncbi.nlm.nih.gov/pubmed/25694784">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4963 href="http://dx.doi.org/10.1155/2015/903541">Publisher Full Text </a> | <a target=xrefwindow id=d6336e4966 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4324745">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726910190">F1000 Recommendation</a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d6336e4980 class=n-a></a>Douglass JA, Carroll K, Voskamp A, <i> et al.</i>: Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient. <i>Allergy.</i> 2010; <b>65</b>(7): 926‚Äì7. <a target=xrefwindow id=d6336e4991 href="http://www.ncbi.nlm.nih.gov/pubmed/19889117">PubMed Abstract </a> | <a target=xrefwindow id=d6336e4994 href="http://dx.doi.org/10.1111/j.1398-9995.2009.02259.x">Publisher Full Text </a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726910195"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6336e5003 class=n-a></a>Paraskevopoulos G, Sifnaios E, Christodoulopoulos K, <i> et al.</i>: Successful treatment of mastocytic anaphylactic episodes with reduction of skin mast cells after anti-IgE therapy. <i>Eur Ann Allergy Clin Immunol.</i> 2013; <b>45</b>(2): 52‚Äì5. <a target=xrefwindow id=d6336e5014 href="http://www.ncbi.nlm.nih.gov/pubmed/23821833">PubMed Abstract </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726910195">F1000 Recommendation</a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726910209"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6336e5027 class=n-a></a>Kibsgaard L, Skjold T, Deleuran M, <i> et al.</i>: Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis. <i>Acta Derm Venereol.</i> 2014; <b>94</b>(3): 363‚Äì4. <a target=xrefwindow id=d6336e5038 href="http://www.ncbi.nlm.nih.gov/pubmed/24162824">PubMed Abstract </a> | <a target=xrefwindow id=d6336e5041 href="http://dx.doi.org/10.2340/00015555-1687">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726910209">F1000 Recommendation</a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a name=d6336e5054 class=n-a></a>Beck LA, Marcotte GV, MacGlashan D, <i> et al.</i>: Omalizumab-induced reductions in mast cell FcŒµRI expression and function. <i>J Allergy Clin Immunol.</i> 2004; <b>114</b>(3): 527‚Äì30. <a target=xrefwindow id=d6336e5065 href="http://www.ncbi.nlm.nih.gov/pubmed/15356552">PubMed Abstract </a> | <a target=xrefwindow id=d6336e5068 href="http://dx.doi.org/10.1016/j.jaci.2004.06.032">Publisher Full Text </a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a name=d6336e5077 class=n-a></a>Oliver JM, Tarleton CA, Gilmartin L, <i> et al.</i>: Reduced FcŒµRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy. <i>Int Arch Allergy Immunol.</i> 2010; <b>151</b>(4): 275‚Äì84. <a target=xrefwindow id=d6336e5088 href="http://www.ncbi.nlm.nih.gov/pubmed/19844128">PubMed Abstract </a> | <a target=xrefwindow id=d6336e5091 href="http://dx.doi.org/10.1159/000250436">Publisher Full Text </a> | <a target=xrefwindow id=d6336e5095 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2853585">Free Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 14 Nov 2016</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/5-2666&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/5-2666&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Allergy, Hospital Universitario Ram&oacute;n y Cajal, Madrid, 28034, Spain<br/> <sup>2</sup> Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, 45071, Spain<br/> <sup>3</sup> Centro de Investigaci&oacute;n del C&aacute;ncer/IBMCC (CSIC/USAL), Departamento de Medicina, IBSAL and Servicio General de Citometr&iacute;a, University of Salamanca, Salamanca, 37007, Spain<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/5-2666/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 14 Nov 2016, 5:2666 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.9565.1">https://doi.org/10.12688/f1000research.9565.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> ¬© 2016 Gonz√°lez-de-Olano D <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=10302 data-id=9565 data-downloads="" data-views="" data-scholar="10.12688/f1000research.9565.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/5-2666/v1/pdf?article_uuid=2828ce9d-4c6e-44af-8c8a-377c6508a605" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.9565.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Gonz√°lez-de-Olano D, Matito A, Orfao A and Escribano L. Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes [version 1; peer review: 2 approved] <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2666 (<a href="https://doi.org/10.12688/f1000research.9565.1" target=_blank>https://doi.org/10.12688/f1000research.9565.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=9565 id=mobile-track-article-signin-9565 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/9565?target=/articles/5-2666"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=10302 /> <input name=articleId type=hidden value=9565 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Lawrence B Afrin</strong>, Division of Hematology, Oncology and Transplantation, University of Minnesota, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Gandhi Damaj</strong>, Institut d'H√©matologie de Basse Normandie, Centre Hospitalier Universitaire (CHU), France </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 14 Nov 2016</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/5-2666&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/5-2666&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=18049-17562></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=18048-17563></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/5-2666/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>14 Nov 16</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Lawrence B Afrin</strong>, Division of Hematology, Oncology and Transplantation, University of Minnesota, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Gandhi Damaj</strong>, Institut d'H√©matologie de Basse Normandie, Centre Hospitalier Universitaire (CHU), France </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/5-2666&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/5-2666/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Advances in the understanding and clinical...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/5-2666/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/5-2666/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/5-2666/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Gonz√°lez-de-Olano D et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/5-2666/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/5-2666",
            templates : {
                twitter : "Advances in the understanding and clinical management of mastocytosis.... Gonz√°lez-de-Olano D et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/5-2666/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/9565/10302")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "10302");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "17562": 0,
                           "17563": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "60e96cb1-f931-4367-9982-dafaf6e6a323";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2666.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2666.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2666.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/5-2666.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/5-2666.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>